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Your editor bids farewell
This issue of Yale Medicine 
marks my last as editor. I have 
retired, effective September 
29 of this year, almost 20 years 
after I started working as Yale 
Medicine’s first staff writer. 
When I started in 1998, only 
three other people worked 
on the magazine. Michael 
Fitzsousa, who was then the 
editor, now works in develop-
ment. Cheryl Violante and Claire 
Bessinger have job titles that 
don’t do justice to all they do 
that makes it possible to publish 
Yale Medicine.
My first big assignment 
was a feature article about 
the newly formed Center for 
Interdisciplinary Research on 
AIDS. My reporting took me 
from the streets of Hartford, 
where I shadowed outreach 
workers who were trying to 
penetrate drug networks, to 
laboratories at Yale, where sci-
entists were seeking treatments 
for AIDS. Since then I’ve traveled 
to Russia and Uganda to cover 
international collaborations, 
reported on student efforts to 
save the Affordable Care Act, 
and overseen our special bicen-
tennial edition, a photo-essay 
by six photographers who docu-
mented a week in the life of the 
School of Medicine.
Over these years, I’ve 
indulged in what makes jour-
nalism such a rewarding call-
ing—the ability to approach 
remarkable people and talk to 
them about what they’re doing. 
It’s taken me into the labs, clin-
ics, and classrooms here at 
Yale, and opened doors in New 
Haven and beyond.
As editor, I’ve had the 
pleasure―indeed, the joy―of 
working with talented writ-
ers and photographers who 
took on myriad assignments 
with energy and enthusiasm. 
Their efforts have made the 
magazine shine, and we’ve had 
the honor of winning silver and 
gold medals from the Council 
for Advancement and Support 
of Education (CASE). Along 
the way, the magazine and its 
writers and designers have 
garnered multiple individual 
awards, not only from CASE, 
but also from the Association 
of American Medical Colleges 
and the American Medical 
Writers Association.
In my mind, however, the 
greatest accolades have come 
from the people who make up 
the School of Medicine com-
munity—the students who told 
me an article in the magazine 
tipped the scales and made 
them decide to study medicine 
here; the physician who asked 
that I put him in touch with stu-
dents who had formed a clinic 
in Nepal so that he could learn 
from them how to make alumni 
service trips more sustainable; 
a request from Yale’s Office of 
New Haven and State Affairs for 
100 copies of our Spring issue 
on the medical school’s relation-
ship with the city.
It’s been a glorious ride, and 
I thank all of those—too many 
to name—who have worked 
with me and from whom I have 
learned so much. The magazine 
has long played an important 
role in engaging and uniting the 
medical school community, and 
I am grateful and honored to 
have had a part to play.
Finally, I welcome Adrian 
Bonenberger as the new editor 
of Yale Medicine. Adrian, a Yale 
College graduate, comes to us 
from Ukraine, where he’s been 
working as a freelance journalist. 
Previously, he served in the U.S. 
Army, leaving as a captain after 
two tours in Afghanistan. He’s 
also a graduate of the Columbia 
University Graduate School of 
Journalism. I wish him well as he 
takes the reins of the magazine 
that has long served the School 
of Medicine community.
John Curtis, Yale Medicine,  
1998-2017
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letter from the editor
  Cultural heritage to the  
microbiome: research at West Campus
w hen scot t a.  strobel, ph.d.,  became vice president for West Campus 
Planning and Program Development in 2011, the 100-plus acres in West Haven and 
Orange had a work force of 84. Now, the population exceeds 1,500 across seven 
research institutes and the School of Nursing. At West Campus, the goal is to promote 
“collisional frequencies” that place researchers from different fields alongside one 
another. Strobel recently spoke with Yale Medicine about the vision for West Campus.
What is the vision for West Campus? We’re trying to set up an incubator to bring together people 
from different departments who would never bump into one another. Then we have them focus on 
a common set of problems. They work in a common lab space, so engineers may be next to geneti-
cists who are next to evolutionary biologists.
Was that the plan when Yale bought West Campus in 2007? Usually when you have a new building, 
you’ve planned it for years, so the day it’s built you know exactly what’s there. One day in October 
2007, we didn’t have the West Campus; then the next day we had 17 buildings and 1.5 million square 
feet of space. Now what are you going to do? The community started throwing out the biggest and 
brightest and best ideas. Michael Donoghue, who became the first vice president of West Campus, 
established the idea for interdisciplinary institutes with faculty from multiple departments.
How do those interactions work in practice? An interdisciplinary neighborhood will draw you in 
different directions than if you’re sitting next to somebody who’s in your field. You might say, 
“There’s someone around the corner who can help me, so I’m going to give this crazy idea a shot.”
How does the West Campus environment differ from being in New Haven?  
We benefit from being near New Haven and our local towns, but you don’t walk out of your lab into a 
city street. There’s one main place to eat. That might look like a weakness, but I think it’s a strength. 
When I started here I invested in the renovation of the conference center and a good environment to 
have lunch. When I go there I’ll see four, five, six faculty members, and sit down and catch up with 
them. People from all over Yale regularly come for retreats, conferences, and symposia. This is a  
















   Deans named to  
 replace Carolyn Slayman
with the passing of carolyn w. slayman, ph.d., in 
December, the School of Medicine lost its first and only 
deputy dean for academic and scientific affairs. She served 
in that position for 22 years, as faculty throughout the 
school marveled at her influence and ability to keep up 
with advances in clinical and biomedical research during 
a time of significant expansion of clinical and basic sci-
ence faculty. It was clear as well that she would be virtually 
impossible to replace. In light of the tremendous growth 
of the medical school as well as the increasing complexity 
of almost every aspect of academic medicine and research, 
her responsibilities have been divided among three deputy 
deanships that were filled in July. 
 
Linda K. Bockenstedt, M.D., the 
Harold W. Jockers Professor of 
Medicine (Rheumatology), will 
serve as deputy dean for faculty 
affairs. Michael C. Crair, Ph.D., 
the William Ziegler III Professor 
of Neuroscience and professor of 
ophthalmology and visual sci-
ence, will serve as deputy dean 
for scientific affairs (basic science 
departments). Brian R. Smith, 
M.D., chair and professor of labo-
ratory medicine, of biomedical 
engineering, of medicine (hema-
tology), and of pediatrics, will 
serve as deputy dean for scientific 
affairs (clinical departments).
“Our new deputy deans will 
work closely as a team to ensure 
that faculty receive the support 
they need to succeed and thrive,” 
said Dean Robert J. Alpern, M.D., 
Ensign Professor of Medicine. 
“I’m confident that they will 
continue Carolyn’s legacy admi-
rably as they implement their 
collective vision on how to best 
support faculty.”
The three deputy deans 
will draw upon their unique 
expertise in their new roles. 
Bockenstedt’s experience 
includes serving as director for 
professional development and 
equity, a position created in 
2006. She became associ- 
ate dean for faculty develop-
ment in 2014. Having worked 
closely with Slayman on faculty 
affairs, she had already taken  
on many of those responsibilities 
in the months leading to her  
new appointment. 
“We’ve had an unprecedented 
number of requests for faculty 
positions from the depart-
ments since January,” she said. 
“Ultimately, we want to help all 
faculty members understand 
their position at Yale along with 
the opportunities available to 
them, the appointments and 
promotions process, and faculty 
development, so they can be suc-
cessful in their careers.” She is 
committed to engaging the entire 
faculty so that they have a voice 
in the decisions that affect them.
Smith views his new posi-
tion as an extension of his role as 
chair of laboratory medicine, in 
which he will continue to serve. 
He recently chaired the Ad Hoc 
Committee on the Clinician-
Educator Track that is charged 
with clarifying and updating the 
track’s criteria for promotion. 
He also chaired the Research 
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be that you could live in a very 
small area of science and know 
all of it,” he says. “Now you have 
to reach out across totally differ-
ent disciplines, which is exciting 
but requires more work.”
Crair served as deputy chair of 
the Department of Neuroscience 
and director of graduate stud-
ies for the department until his 
appointment as deputy dean. A 
team player who is often quicker 
to advocate for his colleagues than 
for himself, he is looking forward 
to making positive contributions 
on a larger scale. “I hope to help 
build the sciences, not just at the 
School of Medicine, but across the 
university,” he said. 
Crair’s vision includes estab-
lishing an environment in which, 
despite the uncertainties of NIH 
funding, the school supports 
investigators at a baseline level 
that allows them to continue to 
do research even in the face of 
funding challenges. “As we get 
older we have more perspective, 
and it’s easier to see past a couple 
Three longtime 
faculty members have 
been named to take 
over the responsi-
bilities of the late 
Carolyn Slayman, who 
served as deputy dean 
for academic and 
scientific affairs for 
more than 20 years. 
From left, Brian Smith 
will oversee scien-
tific affairs for clinical 
departments. Linda 
Bockenstedt will take 
over faculty affairs. 
And Michael Crair will 
handle scientific af-
fairs for basic science 
departments.
Committee of the Association 
of Pathology Chairs. The com-
mittee formulated a physician-
scientist pathway that was 
certified by the American Board 
of Pathology in 2014, a process 
that helped prepare him for his 
position as deputy dean.
Smith acknowledges that 
the challenges he faced when 
he started his career more 
than three decades ago are 
greater, as both the competition 
for research funding and the 
necessity of mastering an ever-
growing body of clinical knowl-


















Kim Guy’s story 
begins in 1966, the 
year she was born in a 
Connecticut juvenile 
detention center, and 
continues through 
foster care, a mother 
with mental health 
problems, and a father 
who died of a gunshot 
wound. Now she uses 
her own experiences 
with drug addiction to 
help others.
For more on Kim Guy,  
visit yalemedicine.yale.
edu/guy
As keynote speaker at the 
17th annual Power Day on May 
12 in Harkness Auditorium, Fink 
observed that people can feel 
powerless in structures that they 
don’t fully control. She referred 
to such physical structures as 
hospitals without clear evacu-
ation plans, and to such insti-
tutional organizations as the 
military or medical field with 
deeply entrenched hierarchies. 
“One thing to take away today—
you do have a lot of power.” 
Much of her talk described the 
moral dilemmas health profes-
sionals faced at Memorial Medical 
Center in New Orleans before 
and after Hurricane Katrina. 
Her 2013 award-winning book, 
Five Days at Memorial: Life 
and Death in a Storm-Ravaged 
Hospital, reconstructs each day 
of the tragedy, sometimes minute 
by minute. Nurses and doctors 
weathered the hurricane, only to 
face a larger crisis as the levees 
broke and the city was flooded. 
Memorial’s backup generators, 
located in the hospital basement, 
eventually quit, leaving medical 
equipment, including life-saving 
ventilators, without power. 
Helicopter and boat evacuations  
faltered. Hospital staff—sleep-
deprived, overworked, and 
exhausted—moved fragile 
patients up and down stairways, 
and passed them through a tun-
nel in a wall for access to the 
hospital’s helipad. Without  
running water, such basic tasks 
as helping patients relieve  
themselves turned into labo-
rious undertakings. 
of years of fluctuations,” he said. 
“But for our junior faculty, not 
knowing the future of research 
funding can be debilitating.” 
He will also look for ways to 
increase diversity, noting that 
“we learn from those diverse 
views—in part shaped by diverse 
backgrounds—that bring a dif-
ferent perspective.”
All three will continue to lead 
active research programs. Crair 
has developed optical imag-
ing techniques to study neural 
development. He has made fun-
damental contributions to the 
understanding of neural activ-
ity in the developing brain and 
demonstrated that early spon-
taneous activity as the brain is 
forming is an essential part of 
normal brain development. He is 
currently exploring the mecha-
nisms by which this activity is 
generated and how it shapes 
brain circuit development. 
Smith conducts bench and 
clinical research on the inter-
face between inflammation and 
coagulation, focusing on bioma-
terials and the pathophysiology 
of blood disorders caused by 
immune reactions. He also stud-
ies cellular immunotherapies. 
Bockenstedt is internationally 
recognized for her research on 
the host immune response to 
tickborne spirochetal infections. 
Her current research employs 
a systems biology approach to 
understand the diverse clinical 
manifestations of Lyme disease, 
and uses molecular profiling to 
identify host factors that deter-
mine the outcome of infection.
As deputy deans, the three 
professors are beginning to 
function as a unit as they work 
across departments to provide 
and support academic oppor-
tunities for faculty and promote 
an increased spirit of collabora-
tion in the school’s culture. They 
unanimously acknowledge that 
while Slayman’s shoes are dif-
ficult to fill, they hope that their 
combined efforts and different 
perspectives will afford them 
broader reach as the school con-
tinues to grow. Reflecting on the 
legacy left by Slayman, Smith 
said, “I was fortunate to have her 
as a role model. Now we just have 
to think back and ask ourselves, 
‘What would Carolyn do?’ ”
—Jill Max
»
Navigating power  
structures in medicine
If you feared that colleagues at 
Guantanamo Bay might use your 
psychiatric care notes against 
your inmate patients, what 
would you do? After a natural 
disaster ravaged your hospital’s 
resources and you overheard 
colleagues deciding who should 
live or die, would you speak up? 
Sheri Fink, M.D., Ph.D., a 
Stanford University-trained 
physician, nonfiction author, 
and Pulitzer Prize-winning cor-
respondent for The New York 
Times, described these sce-
narios based on interviews and 
research on the military prison 
in Cuba and the aftermath 
of Hurricane Katrina in New 
Orleans in 2005. 
yalemedicine.yale.edu6
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Power Day’s focus has expanded 
more recently to examining 
power structures in which 
physicians and nurses operate. 
“Political, economic, social, cul-
tural, and physical structures 
are decided, and then those 
structures affect medical care,” 
said Nancy R. Angoff, M.Ed., 
M.P.H. ’81, M.D. ’90, HS ’93, 
one of the founders of the event. 
She encouraged students to 
think about how power shapes 
structure and to examine how 
they can address these issues 
 in the future. “Because you  
will encounter these situa-




New drugs to fight 
resistant bacteria
Earlier this year, Seth Herzon, 
Ph.D., professor of chemistry and 
member of Yale Cancer Center, 
found—quite inadvertently—an 
arresting opening slide for his 
lectures: an image of himself in 
the hospital with an infection 
he had picked up from a cat bite. 
“All right—here it is,” he tells his 
audiences. “Here’s why we need 
to do antibiotics.” 
There’s no denying the medi-
cal need for new and better anti-
biotics—in 2013, the Centers for 
Disease Control and Prevention 
(CDC) reported that 23,000 
Americans die of drug-resistant 
bacterial infections each year. 
Herzon worried he might be one 
of them when oral antibiotics 
failed against his infection. 
later by the National Academy  
of Medicine concluded that 
using DNR orders “as a proxy for 
triage choice is not a good idea,” 
Fink said, adding that in general, 
“it’s hard enough to get people 
to think about end-of-life issues, 
and if patients do not trust how 
DNR will be used, they might 
not choose it.”
In her talk, Fink highlighted 
the plight of Emmett Everett, a 
380-pound patient who, on the 
morning of September 1, asked 
nurses if they were “ready to 
rock and roll” and begin his 
evacuation. By that evening, 
Everett and at least 16 other 
patients were dead, their bod-
ies filled with high levels of 
morphine or the sedative mid-
azolam—in some cases, both—
according to toxicology reports 
and interviews Fink conducted 
with hospital staff.
With some patients—but not 
Everett—near death, the decision 
was made to inject the patients. 
Some doctors and nurses fol-
lowed orders. At least one doctor 
spoke up, outraged that his col-
leagues would knowingly violate 
the Hippocratic Oath. Were the 
staff powerless to make another 
choice? No, Fink told the  
medical and nursing students.  
“I urge you throughout your 
careers to be aware and alive to 
the fact if something is uncom-
fortable,” she said. 
Originally conceived as an 
opportunity for nurses and doc-
tors to examine the power in 
relationships between doctors 
and nurses and their patients, 
It’s important to remember, 
Fink said, that at every step in 
every medical crisis, nurses and 
doctors have a choice. “Who 
do you save first when you 
know you could lose power at 
any moment? Who makes the 
choice? What will be the process 
of making the choice? Who’s in 
the room making the choice?” 
These concerns are related to 
a primary theme in Fink’s book: 
how can doctors and nurses 
ensure that they provide care 
for patients when structures of 
command and order break down 
amid disrupted communications 
and severely limited resources? 
At Memorial, health workers  
decided that the sickest 
patients—including those with 
do not resuscitate (DNR) orders—
were those with the “least to 
lose” and should be evacuated 
last. A study published years 
Pulitzer Prize-winning 
journalist Sheri Fink 
discussed issues of 
power that emerged 
at the military prison 
at Guantanamo Bay 
and a New Orleans 
hospital coping with 




















More than 150 people 
assembled around 
the steps of Sterling 
Hall of Medicine on 
an afternoon in June 
to support the Af-
fordable Care Act of 
2010 (ACA). Through 
a megaphone on 
the steps of the hall, 
speakers told tales 
from their own lives or 
the lives of loved ones 
about how repeal of 
the ACA could affect 
their health care or 
drive them into bank-
ruptcy.
For more on ACA repeal,  
visit yalemedicine.yale.
edu/aca
“My biggest fear was not death 
itself, but what would be on my 
tombstone if I died,” he said.  
“It would be ‘Herzon, ’79–’17  
(cat bite).’ ” Fortunately, his 
infection was cleared up with an 
IV antibiotic. Not everyone’s is.
Our species has been in a 
continuous evolutionary arms 
race with bacterial pathogens for 
decades now, and they seem to be 
gaining the upper hand. Bacteria 
evolve at an alarming pace—some 
species can produce a new gen-
eration in half an hour—and can 
even exchange genetic informa-
tion that confers defenses against 
our antibiotics. Today, some 
infectious bacteria have evolved 
such a degree of resistance that 
they’ve outpaced the production 
of fresh antibiotics.
Herzon’s lab has recently 
developed a way to chemically 
produce pleuromutilin, a fungal 
antibiotic agent. It was isolated 
in the 1950s, but the means of 
creating it “from scratch” in the  
lab—an alluring possibility that 
would enable the production of 
many variations of the drug— 
had always posed a challenge  
to researchers.
“Bacteria can’t find a way to 
evolve resistance to pleuromuti-
lins without killing themselves,” 
Herzon explained. The site 
that pleuromutilin binds to in 
pathogenic bacteria is essential 
for making proteins—and with-
out proteins, the cells cannot 
survive. To this point, bacteria 
have not devised a way to evolve 
resistance without also injuring 
their own protein centers. 
“We have a way now to 
access sites in pleuromutilin 
that were entirely inaccessible 
before,” Herzon said. “And the 
structural data tell us if we 
modify these sites, we’re going 
to get better antibiotics.” 
There are currently one 
pleuromutilin derivative 
approved to treat infections 
in humans, and two used for 
animals in the United States. 
Herzon’s technique opens the 
possibility of developing many 
more to treat a broader range 
of bacterial species. Bacteria 
are classified as either Gram-
positive or Gram-negative (more 
simply, as having one cell wall 
or two). Gram-negative bacteria 
are more difficult to treat, and 
the existing pleuromutilins fight 
only Gram-positive ones. 
“There’s some evidence that 
if we change the structure of 
pleuromutilin, we can get activ-
ity against Gram-negatives,” 
Herzon said. “So that’s what 
we’re really going for.” 
The quest for novel antibiotics 
has fallen almost entirely onto 
universities’ and philanthropies’ 
shoulders. Big pharmaceutical 
companies are reluctant to invest 
in antibiotic treatments (despite 
the urgency), because even suc-
cessful antibiotics offer a meager 
return on investment. 
 “We’ve got a unique oppor-
tunity here to make a dent in 
this problem using the chem-
istry that we’ve developed,” 
Herzon said. “It’s important 
work to do. Resistance to anti-
biotics has been in the literature 
for 30 years. People have been 
aware of it for 30 years—and it 




Some young adults who have inherited heart conditions that put 
them at risk of sudden cardiac arrest require an implantable car-
dioverter defibrillator, or ICD. For years, the conventional wisdom—
as well as professional society recommendations—was that these 
athletes should engage in no sport more strenuous than golf. Now 
a Yale study published in June in Circulation suggests that the risks 
are lower than previously thought. A team led by Rachel J. Lampert, 
M.D., professor of medicine (cardiology), enrolled more than 400 
athletes with ICDs inside and outside the United States in a study 
to determine the risks of sports participation. Every six months 
over four years, the researchers checked in to see whether the ath-
letes had had any adverse event while playing sports. While some 
did have shocks when their defibrillators detected an abnormal 
heart rhythm, none suffered the worst consequences—defibril-
lator failure, injury, or death. “We can’t say all athletes with ICDs 
should do vigorous sports,” said Lampert, “but our data imply that 
this can be an individualized decision between doctor and patient.”
PLAYING SPORTS  
WITH A DEFIBRILLATOR
Scientists have long wondered why coronary artery disease (CAD), which develops over a 
lifetime, has not been eliminated through natural selection. CAD starts in young adults, pro-
gressing over time to become life-threatening. Present in human populations for millennia, it 
is the leading cause of death worldwide. Scientists at Yale and other medical centers have now 
found that genes underlying CAD also contribute to reproductive success. A genomic analysis 
published last summer in PLOS Genetics suggests that natural selection has relatively recently 
preserved genes that contribute to the risk of coronary artery disease because they also 
contribute to better chances of having children. This evolutionary trade-off, said contribut-
ing author Stephen C. Stearns, Ph.D., the Edward P. Bass Professor of Ecology and Evolutionary 
Biology, shows that “babies can break your heart.”
EVOLUTIONARY TRADE-OFF:  
HAVING KIDS WILL BREAK YOUR HEART
An analysis of breast cancer data has called into question 
prevailing beliefs about the value of early detection. The study, 
published June 8 in The New England Journal of Medicine, 
revealed that many small breast cancers have an excellent 
prognosis, not because they are caught early but because 
they are inherently slow-growing. Because these cancers 
often do not grow large enough to become significant within a 
patient’s lifetime, early detection could lead to overdiagnosis, 
said the researchers at Yale Cancer Center. In contrast, they 
noted, large tumors that cause most breast cancer deaths can 
become intrusive before detection by screening mammogra-
phy. “Our analysis explains both how mammography causes 
overdiagnosis and why it is not more effective in improving 
outcomes for our patients,” said Donald R. Lannin, M.D., pro-
fessor of surgery (oncology) and lead author of the paper. 
“More importantly, it questions some of our fundamental 
beliefs about the value of early detection.”






















a collection of recent  
scientific findings
A DECADE AGO,when Yale purchased what is now known as West Campus from Bayer, 
the plan was to focus on cutting-edge science. The 450,000 square feet of lab space 
would be not spillover space, but a place that would foster a fresh approach to raise the 
visibility of science at Yale. 
Now West Campus is home to no fewer than seven institutes covering cancer, 
nanobiology, microbial sciences, and more. “Our true aim,” says Scott A. Strobel, Ph.D., 
the vice president for West Campus planning and program development, “is for true 
convergence in research.”
To that end, West Campus is geared for research that crosses traditional bounda-
ries. Biologists and chemists work with the Institute for the Preservation of Cultural 
Heritage to find ways to preserve ancient texts and scrolls. A molecular biologist and 
synthetic biologist team up to synthesize a type of protein. Nursing students learn 
about medicinal plants on an urban farm. Labs are located alongside labs in different 
fields—the hope is for interesting water cooler conversations. There’s only one cafeteria 
for a reason—to encourage cross-disciplinary gatherings and conversations.
But interdisciplinary research has been going on for as long as physicians have 
turned to geneticists, biologists, and chemists for insights into the workings of  
the human body. And such research continues across the Yale campus. Radiologists  
work with biomedical engineers to tweak DNA and treat disease. Biomedical  
engineers work with dermatologists to develop a safer sunscreen.
In this issue of Yale Medicine, we celebrate science that stretches inter- 
disciplinary boundaries throughout Yale and at West Campus as it celebrates its  
10th anniversary.
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Ten years ago Yale leaders envisioned  
a campus where biologists, chemists,  
physicists, oncologists, informatics experts,  
and scientists from other realms would 
share ideas, think big, and break new 
ground in medical research.
by jenny blair, m.d. ’04 | frank poole photography
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Christopher Incarvito
The key to West Campus, says 
Chris Incarvito, is bringing 
people together in a space 
without walls. “When you talk, 
somebody’s going to hear. …
But that’s a good thing.”
How West Campus is fulfilling its dream
These days, 1,700 people work and learn in the former 
pharmaceutical industrial park. Rinehart sometimes has 
to park a good 100 yards across campus from his lab. But 
as a researcher who thrives on chance encounters with 
colleagues—several of which have led to successful inter-
disciplinary projects—he couldn’t be happier.
“We who came early, we imagined that we would fill 
the institutes with lots of exciting researchers and stu-
dents and postdocs and all sorts of other people. That’s 
actually happened,” says Rinehart, who is now an associ-
ate professor of cellular and molecular physiology and a 
member of the Systems Biology Institute at West Campus. 
“The buildings are almost full everywhere you go. The labs 
and the floors are bustling with activity. There’s just so 
much going on. It’s really a vision as promised.”
In the 10 years since Yale bought the entire 136-acre 
campus from Bayer for $109 million, West Campus has  
become a playground of sorts for researchers willing 
to work across disciplines. The vast campus increased 
Yale’s footprint by 40 percent, adding 17 buildings, 
450,000 square feet of laboratory space, and nearly 
1 million square feet of warehouses, offices, a library,  
a day care, and more. After years of renovation, the 
place now offers what its leaders call a “high colli-
sional frequency,” prompting people to bump into  
one another, start talking about their research, and—
ideally—work together to tackle the most complex 
problems in science. 
Comprising seven research institutes spanning 
health, culture, energy and the environment, the Yale 
School of Nursing, multiple cores and centers with 
equipment to support research, a Landscape Lab for 
sustainability projects, and a conference center and caf-
eteria, West Campus now offers boundless opportuni-
ties for such collisions. The people ranging across its 136 
acres come from all walks of academic life. Postdocs and 
PIs work in its open-plan labs. Ecologists study invasive 
species on the grounds. Nursing faculty conduct 
research in the school’s biobehavioral lab while students 
study genomics and precision health there, then cross 
to its urban farm to cultivate and learn about medicinal 
plants. And everyone eats lunch together.
“Nursing as a STEM discipline is a science of human 
health ecology, supporting humans in the context of 
the many factors that influence wellness and disease. 
So to be ensconced in a literally rich research ecosys-
tem like that on the Yale West Campus is powerful,” 
says Ann E. Kurth, M.P.H., M.S.N. ’90, Ph.D., dean and 
Linda Koch Lorimer Professor of Nursing.
“West Campus is an opportunity to do something 
different—no departmental structures and associ-
ated bureaucracy, no restrictions or mandates on 
where your scientific curiosity leads you,” says John D. 
MacMicking, Ph.D., a Howard Hughes Medical Institute 
(HHMI) investigator and associate professor of micro-
bial pathogenesis and of immunobiology who recently 
joined the Systems Biology Institute. “It’s about bring-
ing unlikely colleagues together to forge a common 
language and create a new lexicon.” 
As interdisciplinary as it can be
The interdisciplinary nature of West Campus was built 
into Yale’s plans for the campus soon after the purchase, 
according to Robert J. Alpern, M.D., Ensign Professor of 
Medicine (Nephrology) and dean of the School of Medicine. 
“A cancer biology institute was something that 
we thought about the first week after the purchase,” 
Alpern recalls. Yale leaders were also enthusiastic early 
on about microbial diversity. And the campus hap-
pened to include a brand-new chemistry building.
So Yale made it happen. The Cancer Biology institute, 
the Microbial Sciences Institute, the Chemical Biology 
Institute, and the Systems Biology Institute were up and 
running by 2010. In 2011, three more opened in quick 
In early 2010, when Jesse Rinehart, Ph.D., then 
a young assistant professor, was setting up his 
lab on West Campus, the place was a ghost town. 




“Nursing as a STEM discipline 
is a science of human health 
ecology. … So to be ensconced 
in a literally rich research eco-
system like that on the Yale 
West Campus is powerful.”
hed
Scott Strobel
“It’s about as interdisciplinary 
as it frankly can be.”
succession: the Nanobiology Institute in January, the 
Institute for the Preservation of Cultural Heritage (IPCH) 
in June, and the Energy Sciences Institute in September.
Each institute comprises a variety of researchers affili-
ated with various Yale departments. (The Systems Biology 
Institute, for example, includes faculty from biomedical 
engineering; ecology & evolutionary biology; immuno-
biology; microbial pathogenesis; physiology; genetics; 
molecular, cellular, and developmental biology; and 
physics.) Each researcher approaches the institute’s cen-
tral scientific questions from points of view born of very 
different training. And West Campus’ open-plan reno-
vated lab spaces mean they see a lot of one another. 
“It’s about as interdisciplinary as it can frankly be,” 
says Scott A. Strobel, Ph.D., the Henry Ford II Professor 
of Molecular Biophysics and Biochemistry and vice 
president for West Campus planning and program 
development. He is also a member of the Chemical 
Biology Institute.
Needless to say, turning an industrial pharma-
ceutical campus into a massive center for academic 
research has taken a tremendous amount of work  
over the years. 
“There were some spaces where we literally walked 
in, turned on the lights, and plugged in our instru-
ments,” Strobel recalls. “But there were some other 
spaces where it looked like a bomb had gone off inside. 
We had to rip everything out and start over.”
Take Yale’s largest building, the Collections Studies 
Center, for example. In this 462,000-square-foot, or 
over-10-acre behemoth, Bayer once churned out aspi-
rin and Alka-Seltzer.
Today, 300,000 of its square feet house the collec-
tions of the Peabody Museum, the Yale University Art 
Gallery, and the Yale Center for British Art. It houses 
the IPCH, where conservators huddle over priceless 
works of art visible to hallway onlookers through gen-
erous windows. Nearby are labs of the Energy Sciences 
Institute’s chemists, physicists, geologists, and engi-
neers, as well as the hulking microscopes and spec-
trometers of the Materials Characterization Core.
In a sunny, open-plan common space where pill-
pressing machines once stood, a scattering of tables 
and chairs stands ready to host conversations amongst 
the experts here.
“It’s like going into a large mall—when you talk, 
somebody’s going to hear. But that’s a good thing,” 
says Christopher Incarvito, Ph.D., director of research 
operations and technology at West Campus.
Renovations in this and other buildings across West 
Campus called for open laboratory floor plans, intrigu-
ing machinery in full view of passersby, smaller offices, 
and spaces that put students and faculty in closer prox-
imity, according to Incarvito. 
“People in general are more densely packed without a lot 
of walls. That’s all that it takes—that and a place to write, a 
place to express yourself, a place to eat, and of course the 
willingness of scholars to come together,” Incarvito says.
Something about being next door to somebody
This structure worked beautifully for Rinehart and 
Farren Isaacs, Ph.D., both of whom are part of the 
Systems Biology Institute. They met shortly after Isaacs 
joined the Institute in 2010. 
  Scott Strobel
 “Our goal is to be able to engage and  
  support the mission of as many  
 schools and departments as we can. 
How West Campus is fulfilling its dream
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At the time, Rinehart, a molecular biologist, was 
wrestling with a problem: how to get bacteria to scale 
up the synthesis of a particular type of protein.  
“We had the product, we had the cellular machinery. 
We just didn’t have a ‘factory,’ ” Rinehart recalls. “It 
was an engineering technique that was showing a lot of 
promise, but there were a lot of challenges that nobody 
really had an answer to.”  
Along came Isaacs, an expert in synthetic biology. 
“If I’m being perfectly honest, an entire field that  
I was almost ignorant of,” Rinehart says. They got  
to talking. 
Isaacs was working on a genetically engineered 
bacterium. It turned out to work perfectly with the 
approach Rinehart’s lab was using. It was “sheer luck,” 
Rinehart says. 
Right away, he recalls, “we were making dream 
molecules at scale, at purity, exactly as we had 
designed. It was this exact blend of two technologies 
from two different planets coming together in the 
same place.” Within two years, the collaborators had 
published in Science and Nature.
“If I had not been at West Campus in systems biology 
working right next door to Farren, I don’t think we 
would have realized what we’ve realized as collabora-
tors,” Rinehart says. “The design of the space, the loca-
tion, the composition—it really matters. There’s just 
something about being right next door to somebody.” 
How West Campus is fulfilling its dream
A meeting of proteomics and ancient art
What happens when you introduce a proteomics 
expert to an art conservator? Insight into ancient 
animal husbandry. This encounter happened on 
West Campus when Brandon Gassaway, a graduate 
student in the Department of Cellular & Molecular 
Physiology and in the Systems Biology Institute, 
worked with Anikó Bezur, Ph.D., the Wallace S. 
Wilson Director of the Technical Studies Lab at the 
Institute for the Preservation of Cultural Heritage.
In collaboration with Yale University Art Gal-
lery conservators Anne Gunnison and Irma Pas-
seri, Bezur’s group was studying a third-century 
wooden shield unearthed by a French-Yale team in 
1935 at a site called Dura-Europos, a former Roman 
border outpost in what is now Syria. Decorated 
with paintings of scenes from the Iliad, the shield 
was made of poplar slats glued together. Bezur and 
her colleagues suspected that the adhesive and 
the paint’s binder were made of animal protein, but 
their techniques didn’t allow them to get more 
specific. Her team asked Jesse Rinehart, Ph.D., as-
sociate professor of cellular and molecular physiol-
ogy, and Gassaway whether they could figure out 
what the ancient artisans used as adhesives. Using 
mass spectroscopy-based proteomics techniques 
and equipment in the West Campus Analytical Core, 
Gassaway found the telltale signature of three pro-
teins in the adhesives. The verdict: cow’s milk. 
This finding was surprising, Bezur says—they 
were expecting a gelatin-based glue between the 
wood slats and egg in the paint—and they’re looking 
to verify it with other techniques. 
“My lab is very excited about being in an envi-
ronment where there’s so much biochemical and 
biological expertise,” Bezur says. “In return, we’re 
able to stretch the relevance of these tools not only 
to address medical questions but also to address 
questions that nurture the soul. Obviously, there are 
not that many lives that get saved by research on 
Roman shields, but … to be able to marshal new tech-
nologies to get at answers we couldn’t even dream 
of before is really amazing. It allows us to be more 
responsible stewards of these treasures that speak 
to our shared human history.”
—Jenny Blair, M.D. ’04
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Anikó Bezur
“We’re able to stretch the 
relevance of biochemical and 
biological tools not only to  
address medical questions, 
but to address questions that 
also nurture the soul.”
Jesse Rinehart
“The buildings are almost full 
everywhere you go. The labs 
and the floors are bustling 
with activity. There’s just so 
much going on. It’s really a 
vision as promised.”
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How West Campus is fulfilling its dream
[For more on their collaboration, see “A Fab Lab 
Collab,” page 26.]
Over lunch and the computer
Two more planned elements of West Campus nurture 
its magical chance encounters, according to Strobel: 
the cores and the cafeteria. 
The cores concentrate shared equipment. Like 
neighbors who agree to share a lawn mower, West 
Campus scientists share expensive tools that they 
might otherwise have kept to themselves. As they con-
gregate at a microscope, spectroscope, or supercom-
puter, they talk to one another. 
As for the cafeteria, it’s a cheerful, busy place whose 
employees are famously warm. It’s been completely 
renovated from its predecessor, which did not encour-
age patrons to linger. The West Campus cafeteria is the 
only place to eat lunch on campus, and that’s on pur-
pose, Strobel says.
“They’re going to be drawn there for lunch, and as 
a result, there’s going to be the opportunity for these 
kinds of conversations to occur,” he says.
The cafeteria is part of a conference center that 
holds departmental retreats and seminars from 
throughout Yale. When faculty present their work, 
West Campus researchers can amble over and listen. 
Rinehart loves that.
“You’re constantly getting exposed to all these differ-
ent fields,” Rinehart says. “We intersect so deeply with 
chemistry, with physics, with medicine, with basic biol-
ogy, with evolution. You’re hitting these major categories 
in depth and breadth that’s just not typically seen on the 
other major centers on campus.” 
A decade after its purchase, the transformation of 
West Campus is almost complete, according to Strobel. 
The science is humming, and the campus plays host to 
many additional thought-provoking activities: confer-
ences of the Yale Women Faculty Forum; architecture 
students’ class on building a prefab house; agricultural 
experiments; summer camps; art installations; and 
police retreats, among many others. In the future, 
West Campus leaders plan to weave in faculty from 
more fields at Yale.
“Our goal is to be able to engage and support the 
mission of as many schools and departments as we 
can,” Strobel says.
Reflecting on how the place has changed, Strobel 
recalls buying lunch at the campus’ old Bayer-legacy 
cafeteria, Grab’n’Go, shortly after his appointment as 
vice president. The difference between then and now 
could stand in for the entire campus.
“Calling it the Grab’n’Go literally was the worst pos-
sible signal: come in, grab an old yucky sandwich, pay 
for it, and eat it at your desk. Two people would come 
in and grab a sandwich and leave, and it’s like, ‘This 
is the dreariest, saddest place. Is this ever going to be 
anything more than it is?’
“And now, the place is alive. It’s just really excit-
ing. It’s been so fun to watch that transformation.”  
/yale medicine
Jenny Blair, M.D. ’04, a freelance writer based in Montpelier, Vt., has 
written frequently for Yale Medicine.
    Jesse Rinehart
  “If I had not been at West Campus in  
 systems biology working right next door to  
  Farren, I don’t think we would have  
 realized what we’ve realized as collaborators. 
A new tool for gene editing offers new 
approaches to prevent disease.
by natasha strydhorst | maya szatai illustration
Adele Ricciardi navigates the corridors and stairways 
of the Hunter Building with practiced ease. The School 
of Medicine has come to feel like home after six years 
spent in its labs and classrooms.
“When I came to medical school, I wanted to find 
research that was translational, bridging the gaps 
between basic science and medicine,” Ricciardi 
says. There’s no doubt she’s found it at the School of 
Medicine. Ricciardi spends her days in three differ-
ent labs, bridging gaps and translating research across 
campus—and disciplines—in the pursuit of her M.D./
Ph.D. degrees. 
Ricciardi’s work is necessarily multifaceted. In the 
landscape of medical research in general, and at the 
School of Medicine in particular, the junctions of tra-
ditionally disparate fields are yielding prolific harvests. 
Collaborative research among Ricciardi’s home-base 
labs has produced a gene-editing tool more precise 
than the much-lauded CRISPR/Cas9, developed a 
nanoscopic vehicle to deliver it, and identified genetic 
ailments that it might alleviate. The tool, triple helix, 
was developed in the lab of Peter M. Glazer, M.D. ’87, 
Ph.D. ’87, HS ’91, FW ’91, chair and Robert E. Hunter 
Professor of Therapeutic Radiology, and professor of 
genetics. Triple helix is the fruit of a collaboration that 
goes back nearly a decade.
In 2009, Joanna Chin, M.D. ’10, Ph.D. ’10, presented 
her research on triple helix at an annual M.D./Ph.D. 
retreat. The DNA-editing tool was promising, but ferry-
ing it safely into cells was proving a seemingly intractable 
challenge. Fortuitously, the nearby poster of Nicole Ali 
McNeer, M.D. ’14, Ph.D. ’14, illustrated the development 
of nanoparticles that could deliver complex molecules—
like DNA—right to the heart of cells. Each quickly real-
ized that the other’s project solved a problem in her own: 
Chin had an editing tool without a delivery vehicle,  
while McNeer’s nanoparticles were ferries in want  
of a payload. 
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“Everybody realized this was a perfect synergism,” 
says Glazer, who was Chin’s principal investigator.  
In the eight years since Chin and McNeer’s serendipi-
tous meeting, the synergism has expanded to produce 
numerous papers and involve many more researchers.  
“It’s been a tremendously productive collabora-
tion,” says W. Mark Saltzman, Ph.D., the Goizueta 
Foundation Professor of Biomedical and Chemical 
Engineering, and professor of cellular and molecular 
physiology, who was McNeer’s principal investigator. 
Elias Quijano, an M.D./Ph.D. student, also works 
in the labs of both Glazer and Saltzman. Initially 
an English major at Yale College, after a class with 
Saltzman, Quijano became a biomedical engineer-
ing major, and later Saltzman’s lab manager. He’s now 
involved in the triple helix research, but that class he 
took as an undergraduate sparked his interest in bio-
medical engineering and medicine.
 “It really came from seeing that first example of 
how science could enter clinical medicine,” he says, 
“and how a clinical need could drive the scientific pro-
cess itself. I think seeing that interplay—seeing that 
dance between science and medicine—was something 
that really attracted me to the field.” 
Like Quijano, Ricciardi works on basic science in the 
labs of both Saltzman and Glazer, refining nanoparticles 
and the genetic payload for them to deliver. She gets her 
clinical fix in the lab of David H. Stitelman, M.D., assis-
tant professor of surgery (pediatrics). “I had an inter-
est in engineering,” Ricciardi says, “because I thought 
it married well with medicine.” The union means she 
can “apply science in a very human way”—a prospect 
eliciting such excitement that it gives her goose bumps. 
At this stage, the applied science is operating in mouse 
models, but the human implications are palpable. 
“If you can essentially cure a disease, or eliminate 
the symptoms of a disease with very few off-target 
effects—I think there’s a huge unmet need there,” 
Ricciardi says. 
Triple helix in action
Ricciardi strides down a final corridor and pulls out her 
ID to unlock the Glazer lab. After greeting lab mates 
and consulting one of several hefty lab notebooks 
to check the DNA concentrations in her upcoming 
experiment, Ricciardi glances at the current research 
subject: F8 571. To an outside observer peering into the 
enclosure, the scurrying creature is an ostensibly aver-
age mouse. On the molecular level, however, some-
thing is dangerously amiss: a single point mutation in 
the mouse’s DNA codes for a rare but injurious blood 
disorder, thalassemia. The condition is characterized 
by weak, quickly expiring red blood cells and result-
ing anemia. The tantalizingly minuscule genetic error 
and its outsize consequences are fueling the efforts to 
rewrite the code—not only for this mouse or this disor-
der but for such notorious conditions as cystic fibrosis 
and sickle cell anemia in human patients.
The genetic revision begins with a DNA analog (pep-
tide nucleic acid, or PNA). Encased in a nanoparticle, 
the PNA gains access to cells’ DNA—and the disease-
causing mutation in it. Guided by its sequence, which 
will seek out its match in the DNA, the engineered PNA 
snakes alongside and around the snippet of errone-
ous DNA, gently dislodging and taking the place of its 
partner strand. Binding to either side of the DNA, this 
Biomedical engineering meets radiology meets genetics
  Mark Saltzman
 “Peter [Glazer] and I have very little  
overlap in terms of our scientific disciplines,  
  but as a team we could make  
 progress on problems that neither  
   one of us could easily do alone. 
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new filament distorts the classic ladder-like helix to 
form a temporary triple helix: PNA-DNA-PNA. This 
aberrant arrangement sets off warning bells in the 
cell’s machinery. The perturbed cell senses the dis-
tended bulge in its genetic makeup—much as you 
would a pebble in your shoe, Glazer says. The conspicu-
ous arrangement spurs the cell’s repair mechanisms, 
which hasten to slip a pristine piece of donor DNA (also 
delivered by the nanoparticle) into the damaged gene, 
repairing the initial mutation. 
Triple helix has been used to correct the thalassemia-
causing mutation in a mouse model. “We cured mice 
of anemia,” Glazer says. “We did four injections of 
nanoparticles, and 30 days later, they were cured.” The 
technology is less active than the common gene-editing 
CRISPR/Cas9—repairing about 5 percent of target cells, 
while CRISPR will act in 30 to 50 percent. However, 
the off-target effects (creating unwanted mutations 
elsewhere in the genome) are also much lower in triple 
helix than in CRISPR—10,000- to 100,000-fold lower. “I 
think people will improve the CRISPR nuclease to make 
it a little bit less promiscuous—but we’re already there,” 
Glazer says. “I think we have fewer off-target effects 
than CRISPR will ever be able to get to.” Glazer expects 
triple helix to be in a clinical trial within two years. 
 “We’re now at a stage where we’ve had advancements 
in PNA design and advancements in drug delivery con-
verging,” Quijano says. “We’re getting to a place where 
both technologies are ready for clinical translation.” 
A dystopian future?
For many, the prospect of human gene editing raises 
the unsettling specter of a dystopian world in which 
elites create custom children with enhanced mental or 
physical agility—or even purely aesthetic characteris-
tics such as a specific eye or hair color. 
“I have very distinct memories of being in my high 
school biology class, and them wheeling in the TV on the 
cart and watching Gattaca,” says Ricciardi. The 1997 film 
starring Ethan Hawke portrays a future world in which 
genetically engineered children excel, while natural ones 
come up against continuous prejudice. The work coming 
out of the Glazer and Saltzman labs has a more virtuous 
goal. “We are not trying to introduce favorable character-
istics such as improved intelligence or athletic ability or 
musical prowess. What we’re trying to do is eliminate the 
burden of disease in children,” Ricciardi says. “There are 
kids with genetic disorders who will be going to doctors’ 
appointments for the rest of their lives. They’re going to 
be taking chronic expensive therapies to help ameliorate 
the symptoms of their disease. And if we can do anything 
to lessen that burden on patients, families, and the health 
care system—that’s what the goal of our therapies is.” 
“The most exciting aspect of it is seeing how these 
molecules can be applied clinically, and seeing the 
potential for curing human disease,” Quijano says. 
Saltzman has been pursuing interdisciplinary 
research since his graduate school days, studying 
chemical engineering and then medical engineering to 
become a biomedical engineer. Immersion in the two 
worlds of engineering and medicine, he says, paved the 
way to being a collaborative scientist. “So much of it is 
about understanding the culture and understanding 
the language that people use,” he says. 
“Many easy problems have been solved, so the prob-
lems we’re working on now are much harder. That’s 
why many of them involve collaborative teams of 
people—often people with different kinds of expertise,” 
Saltzman says. So-called easy problems have their 
questions and answers in the same discipline, whereas 
hard problems draw both from multiple fields. “Peter 
[Glazer] and I have very little overlap in terms of our 
scientific disciplines, but as a team we could make 
progress on problems that neither one of us could 
easily do alone,” Saltzman says. 
Glazer and Saltzman’s collaboration has been pro-
lific—producing papers, patents, and partnerships—and 
it’s now becoming prototypical. Yale, Saltzman says, 
is “a sprawling university—intellectually—but a pretty 
compact university, and one where community is really 
valued. It’s big enough that there are all sorts of different 
people here—with all different sorts of expertise—but 
it’s small enough that they’re not all that hard to find.” 
A multidisciplinary environment is, perhaps paradoxi-
cally, where such researchers as Quijano, Ricciardi, 
Saltzman, and Glazer are finding their niche. 
“It’s just essential for me to collaborate with  
people,” Saltzman says. “I couldn’t be competitive  
if I didn’t.” /yale medicine
Natasha Strydhorst was Yale Medicine’s summer writing intern in 2017.
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Jesse Rinehart had a protein he wanted to fabricate 
in bacteria; Farren Isaacs had the perfect bacte-
rial factory. Isaacs moved into the lab next door to 
Rinehart’s, and the rest is history.
by ashley p. taylor | frank poole photography
yalemedicine.yale.edu26
Next-door lab neighbors 
Jesse Rinehart and Farren 
Isaacs had shared interests 
and complementary tools. 
Together they have opened 
doors in systems biology.
Rinehart, M.S. ’99, Ph.D., ’04, associate professor of 
cellular and molecular physiology, studies how phos-
phorylation—the addition of a phosphate chemical 
group to proteins and other molecules—changes the 
way cells behave. Phosphorylation is critical for many 
cellular functions—along with dephosphorylation, it 
can turn enzymes and receptors “on” and “off”—and 
in humans there are an estimated 230,000 phospho-
rylation sites. Phosphorylation is the cell’s most com-
mon tool for regulating protein function and passing 
on signals. It may sound like the nitty-gritty, but it 
affects human health in a big way: phosphorylation 
defects can cause high blood pressure, the spread of 
cancer, and other medical problems. 
At the time he started his job on West Campus, 
Rinehart had developed a bacterial system for adding 
phosphate groups to proteins to study their effects. But 
his system didn’t work very well in the bacteria that he 
was using. “We had invented this amazing manufactur-
ing process that was going to change the world, but we 
didn’t have the right factory,” Rinehart says. “We were 
forced to make this in our garage with crappy materials 
and things that barely worked.” In Isaacs’ unpublished 
work, Rinehart saw that he had created a bacterial strain 
that would be the perfect manufacturing plant. “All we 
had to do was install our technology into this factory, and 
all of our problems would be solved,” Rinehart says.
That’s essentially what happened. As soon as Isaacs, 
now an associate professor of molecular, cellular, and 
developmental biology, accepted Yale’s offer and 
moved into the lab next door to Rinehart’s, they set to 
work building Rinehart’s phosphorylated proteins in 
Isaacs’ bacteria. “Not only did we have exciting, very 
complementary research programs, but we started 
at the same time, we were right next door to each 
other, we were similar in mind and spirit and scien-
tific method—it was just a really, really good match,” 
Rinehart says. Now they are using their bacterial facto-
ries to develop treatments for glioblastoma. Specifically, 
they are making large amounts of a protein that 
becomes active when phosphorylated and causes brain 
tumors to spread. The researchers can then screen for 
drugs that would inhibit that protein and stop tumors 
in their tracks.
Changing the genetic code
Rinehart has sought in his research to understand what 
happens when a protein gets phosphorylated. “How 
does it change the properties of the proteins? Does it 
make them more active? Does it turn them off like a 
switch?” Of particular interest to him is phosphoryla-
tion of the amino acid serine, one of the 20 amino acids 
that make up proteins. Serine phosphorylation is the 
most frequently used signal in the cellular communi-
cations that control most physiological processes. The 
simplest way to study phosphorylation’s effects on pro-
tein function would be to make two versions of the pro-
tein, one phosphorylated, one not, and compare their 
activities. But there was no easy way to alter a protein’s 
phosphorylation status. 
A fab lab collab
It was 2010 and Jesse Rinehart’s first day as the head of 
his own lab and a faculty member at Yale’s West Campus 
when an email requested his presence at a meeting to 
discuss a new recruit—a scientist whom the Systems 
Biology Institute hoped to lure to West Campus to start 
a lab. As soon as Rinehart saw what Farren Isaacs, M.S., 
Ph.D., was working on, he became very excited. “I was 
like, ‘Oh, my god, I hope this guy comes,’ ” Rinehart  
says. Isaacs’ current work, he saw, held the solution to  
a problem that he faced in his own research.
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Given what we know about the genetic code, however, 
it was fairly easy to alter a protein’s amino acid sequence: 
genes, made of DNA, encode proteins, and, on a smaller 
scale, three-letter stretches of DNA called codons code 
for amino acids. To find out how one amino acid affects 
a protein, scientists can add or delete its codon. Rinehart 
used this approach to figure out a way to study phospho-
rylation in bacteria. Only to do it, he had to expand 
the genetic code to include a new amino acid that was 
already phosphorylated, plus its corresponding codon. 
With an expanded genetic code that included phospho-
rylated serine, or phosphoserine, Rinehart reasoned, he 
could program a phosphate group into a protein by add-
ing its codon into that protein’s gene.
Putting this approach into practice was not without 
its hurdles. All the DNA codons already encoded other 
things—amino acids or stop signals, which tell the cell’s 
protein production machinery to release the finished 
protein. Luckily for Rinehart, the genetic code is redun-
dant: more than one codon represents each amino acid, 
and the same goes for the stop signal. Rinehart used a 
stop codon called the amber stop codon to encode phos-
phoserine. The bacterial cell would still have other stop 
codons that could signal “stop.”
Rinehart also had difficulties at the protein produc-
tion level. To make a protein, a gene—essentially a series of 
codons—is copied into a messenger RNA. The messenger 
RNA, also a collection of codons, travels to the cell’s pro-
tein production machine, where transfer RNA matches the 
codons and amino acids in a process called translation. 
To make sure that the amber stop codon would encode 
phosphoserine, Rinehart needed transfer RNAs that 
were attached to phosphoserine and would recognize 
the codon. While working on his doctoral dissertation, 
he worked closely with a team that discovered a protein 
that attaches phosphoserine to transfer RNAs, and by 
2011, he had developed a translation system that inserted 
phosphoserine wherever the amber stop codon appeared. 
Sounds great, right? But exciting as it was, Rinehart says, 
there was also “a major, major problem.”
The bacterial cell had competing systems that trans-
lated the amber stop codon in different ways. The bacte-
rial cell recognized it as a signal to stop translating and 
release the finished protein; Rinehart’s transfer RNAs 
recognized it as a signal to insert phosphoserine. That 
competition rendered the technology weak, Rinehart 
says. “We could make the proteins we wanted, but there 
were very low levels; it was almost trace amounts.”
Rinehart was attacking that problem when Isaacs 
arrived with a bacterium he had created that solved the 
problem. In his bacterial strain, Isaacs had replaced the 
amber stop codon with another stop codon throughout 
the entire genome and deleted the factor that recognized 
it as meaning “stop.” The amber stop codon took on a 
new meaning—not “stop,” but “insert phosphoserine.” 
“We could easily take our genetically recoded 
organisms and his phosphoserine system and bring 
them together, and start to produce custom-designed 
phosphorylated amino acids, phosphorylated proteins,” 
Isaacs says. As they reported in a 2013 paper published 
in Science, the system worked well: in their bacteria, 
wherever the amber stop codon occurred in RNA, the 
cell translated it as phosphoserine in the resulting pro-
tein. This system would later allow them to study how 
phosphorylation of a specific protein causes brain cancer 
to spread, and to look for drugs that, by blocking phos-
phorylation, may be able to stop the cancer’s progress.
Rinehart and Isaacs decided to study a kinase, a 
protein that, when active causes brain tumors to 
spread. And it becomes active, they found, when it is 
phosphorylated. Their approach appears counterintui-
tive. Rather than inhibiting phosphorylation, they first 
used their bacterial factories to generate large amounts 
of the phosphorylated active kinase. Then they 
screened for drugs that would inhibit not only that 
kinase, but also, they hoped, cancer’s spread. They’ve 
found some candidate treatments that prevent the can-
cers from migrating in a tissue-culture dish. Now they 
are testing these candidate drugs in mice implanted 
with human brain tumors. They hope that in the 
future, such a compound could prolong human lives.
“It’s a great collaboration,” Isaacs says. “We have 
developed a great environment to do this work that 
really lies at the interface of multiple disciplines, and  
I think that’s really allowed us to sort of do things and 
achieve things in our science that independently we 
wouldn’t have been able to do. And that’s precisely 
what science is about and what collaboration in science 
is about.” /yale medicine
Ashley P. Taylor is a frequent contributor to Yale Medicine.
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Clinicians at the Child Study Center worked with 
experts in genetics, neuroimaging, and eye tracking 
to understand what causes childhood disintegra-
tive disorder, a rare form of autism.
by rachel horsting | maya szatai illustration

That changed at the end of third grade. Dylan entered a 
period of intense anxiety that lasted nearly six months. 
In a video from this phase, he frantically paces his liv-
ing room, shaking his hands, scratching his shoulders, 
repeating over and over, “I’m upset. … I don’t like it. … 
oowww, it hurts. … I’m scared.” He scratches under 
his shirt, giving the impression he wants to crawl out 
of his skin. “He cried all the time,” Covell recalls. “I’m 
convinced when he was looking at me, he was seeing a 
distorted version of me.” As this phase of terror ended, 
Dylan started new, dangerous behaviors. He jumped 
from high places and darted into the road. He devel-
oped tics and licked surfaces. Then he slowly ceased 
talking, began to lose vocabulary, and used simpler 
sentences. When his scores on his developmental 
evaluations dropped in every single area, his family 
convinced his school to get him evaluated at the Yale 
Child Study Center (YCSC).
In advance of the visit, Covell shared the videos 
of Dylan at the ages of 3 and 8 with clinicians at the 
YCSC. A final video shows him sitting limply in front 
of a puzzle, staring around the room. Occasionally, 
he picks up a piece and shows it to the camera before 
setting it back down. He does not speak. Minutes 
after the video ended, Fred R. Volkmar, M.D., the 
Irving B. Harris Professor in the Child Study Center 
and professor of psychology, and Alexander Westphal, 
M.D., HS ’11, Ph.D. ’12, FW ’12, assistant professor of 
psychiatry in the YCSC, broke the news: her son had 
childhood disintegrative disorder (CDD). 
The diagnosis offered little comfort. “It put a name 
to it, but it didn’t really help,” Covell says. What the 
family learned was terrifying: there is no treatment for 
CDD, and Dylan will likely need special services and 
support for his entire life. But in those first few years, 
Covell says, things were OK. “It was challenging—he 
lost a lot of speech and some of the joy, but he was still 
involved in the family.” From fifth through 10th grade, 
the family worked with the public school system to 
get Dylan the support and accommodation he needed. 
Covell said it was especially difficult to get the schools 
to understand Dylan’s new reality. “He’s different from 
your typical kid with autism.”
As a result of years of advocacy, Covell, an assistant 
editor for the Press News Group in Southampton, N.Y., 
started a summer camp specifically tailored for kids 
on the autism spectrum, pairing them with typically 
developing peers. Now, she figures she has seen just 
about every variety of autism. This exposure, however, 
makes her uncomfortable putting Dylan’s experience 
and her family’s challenges on the same spectrum.  
“I have friends whose kids have autism and are going to 
college. My kid can’t wash his hair. It’s not only hard  
to think of those as the same thing; it’s absurd.”
The mystery of what is really going on with her son 
has kept her connected to Yale, and committed  
A catastrophe in the brain
Dylan started life as a typical baby, meeting his mile-
stones for walking, talking, and other markers of 
normal development. In a home video from when 
Dylan was about 3, he climbs, bursting with energy, 
on the couch and pretends to read aloud from a pic-
ture book. His conversation is animated as he talks 
about the book with his father, who is recording, 
and he speaks in full sentences. In kindergarten, his 
parents noticed some language delays, and Dylan 
received special education support, but his mother, 
Kim Covell, saw him as “just a quirky kid.”
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to participating in any research that might help scien-
tists better understand autism and CDD. 
A rare and devastating disorder
CDD, which affects between one and two children in 
100,000, was first identified in 1908. It is also known 
as Heller’s syndrome, for the Austrian educator 
Theodor Heller, who identified the disorder 35 years 
before autism was first described. Westphal, one of 
the doctors involved with Dylan’s case, describes 
CDD as what happens when normal kids suddenly 
develop autism. They lose acquired language; motor, 
social, and play skills; and frequently bladder and 
bowel control. The loss often follows a period of such 
psychiatric disturbances as hallucinations and anxi-
ety, similar to Dylan’s six-month period of terror. In 
2013, CDD, then a distinct disorder, was incorpo-
rated into autism spectrum disorder (ASD) in DSM-5, 
the Diagnostic and Statistical Manual of Mental 
Disorders used by psychologists and psychiatrists. 
This reclassification has diminished awareness of the 
disorder, making it harder for families to find infor-
mation and researchers to secure grant money. 
This DSM-5 reclassification is a mistake, according 
to Abha Gupta, M.D., Ph.D., FW ’07, assistant professor 
of pediatrics, who became interested in CDD during 
her fellowship at Yale. Although people with CDD meet 
the full criteria for autism—characterized by difficul-
ties in social communication and restricted, repetitive 
patterns of behavior—the clinical history of the dis-
order is different. It is distinguished by its late onset—
starting any time between the ages of 2 and 10—and 
involves dramatic regression and severe impairment. 
YCSC faculty have researched CDD for more than 
20 years, starting with Volkmar, the center’s former 
director. Through word of mouth, families affected by 
CDD referred one another to the YCSC for evaluation, 
building up a community of families like Dylan’s that 
are committed to seeking answers for a condition that 
has no treatment. 
In addition to the desire to understand a mysterious 
and devastating disorder, the interest in studying CDD 
comes partly from what it could say about all of autism, 
says Westphal. The conventional wisdom on autism is 
that it is a developmental disorder existing from the 
beginning and that different individuals are affected 
by atypical development in various areas of communi-
cation and social learning to differing degrees, hence, 
its description as a spectrum disorder. 
But Westphal describes CDD as more of a global 
catastrophe in the brain—low-functioning autism by 
a different pathway. “That’s significant because it may 
illustrate that not all people with low-functioning 
autism have the same kind of autism as people with 
high levels of function.” 
Gupta and Westphal were two of the lead researchers  
on a team composed of geneticists, clinicians, neuro-
imaging experts, and eye-tracking scientists to per-
form a neurogenetic analysis of CDD. They identified 
genetic mutations associated with it, mapped its pat-
tern of abnormal brain activity through functional 
magnetic resonance imaging (fMRI), and charted its 
social activity through eye tracking. In every area, 
patients with CDD were compared to those with 
autism, both with intellectual disability and without, 
and to typically developing controls. The team hoped 
these data could help them understand what happens 
in the brains of kids like Dylan, and how similar it is  
to more common subtypes of autism. 
The genetic analyses showed important differences 
between CDD and most forms of autism. Not only were 
different genes involved, but so were the brain regions 
where these genes were active. The genes most likely 
to be involved in CDD were expressed strongly in non-
neocortical regions of the brain, which help control 
eye movements and attention to social information. 
ASD genes are more strongly expressed in neocortical 
regions. Another analysis showed that the pattern of 
expression of potential CDD genes had the most simi-
larity to autism cases with a history of regression, sug-
gesting that regression might have a distinctive genetic 
pattern. The symptoms seen in CDD, this finding sug-
gests, are likely caused by a genetic mechanism in the 
brain different from most other subtypes of autism.
The team used non-sedated fMRI to see patterns of 
brain activity when the research participants looked 
at images of emotional faces (a social stimulus) and 
houses (a neutral stimulus). The study also, for the 
first time, included patients with intellectual dis-
abilities in addition to their autism—a group that is 
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A catastrophe in the brain
underrepresented in imaging studies because it is  
difficult to get these patients to cooperate with the 
study protocols.
The CDD cohort had an abnormal pattern of activity 
in nonneocortical brain regions when viewing faces 
versus houses, a departure from the abnormal pattern 
that people with high-functioning autism exhibit. The 
low-functioning group had a pattern between those of 
the CDD and high-functioning autism groups. 
The researchers also found a surprising convergence 
between the genetic and neuroimaging tests—the 
regions that were abnormally overactive in people 
with CDD were the same regions where CDD candidate 
genes are most active.
Eye-tracking studies record what research partici-
pants look at when shown pictures or videos. When 
viewing faces, most of us look at the eyes, while 
high-functioning individuals with autism split their 
time between the mouth and eyes. This difference is 
thought to explain some social skills deficits found in 
people with ASD. Because people with CDD are more 
severely affected than average, Gupta expected to find 
an abnormal eye-tracking pattern. Instead, she found 
that people with CDD focused on the same things as 
typically developing people did. “They also favored the 
eyes when viewing faces,” Gupta says.
The clinical observations, genetic analyses, and 
imaging and eye-tracking data converged in several 
areas. First, the genes that are most likely to be involved 
in CDD are very active in the same areas that are overac-
tive when people with CDD looked at faces. Along with 
this abnormal overactivity came increased attention to 
the eyes. The researchers speculate that because CDD 
surfaces after prolonged normal development, the neu-
ral circuits that control attention to faces may be pre-
served. If so, then whatever is happening in the brain 
during the regression in CDD does not change how the 
brain processes faces. Why the preservation of some 
neural circuits is still accompanied by the severe behav-
ioral symptoms of CDD remains a mystery.
A distinct disorder
Studies like this, says Westphal, are notable and 
should push a rethinking of the definition of autism. 
He favors modeling it as “a converging constellation,” 
in which multiple pathways meet to present similar 
symptoms. “For me, CDD is so much at the center,” 
says Westphal. “It’s the canary in the coal mine, 
marking the possibility that gradual developmental 
accounts do not explain all forms of autism.”
The distinction has clinical implications. With a 
CDD diagnosis, the initial push is to hunt for a revers-
ible cause. If the patient is diagnosed with autism and 
intellectual disability instead, that hunt never happens. 
“This means we may be missing a whole world of pos-
sible treatments for kids on the low-functioning end,” 
says Westphal.
Pamela Ventola, Ph.D., FW ’08, assistant professor 
in the YCSC, helped lead the team that evaluated the 
research participants. She believes that this study sup-
ports her hunch that CDD is its own entity. In other 
research, she has predicted the effectiveness of a par-
ticular treatment based on brain images of patients. 
CDD “feels very different, clinically,” she says. Even 
though many of the behavioral features are the same as 
those of autism after the regression has passed, Ventola 
thinks the results suggest that CDD may be an entity 
distinct from ASD. “This interdisciplinary research 
is really the key—none of these methods alone would 
have given these results,” she says.
James C. McPartland, Ph.D., an associate professor 
in the YCSC who wasn’t involved in this study, is skep-
tical about abandoning the spectrum model for kids 
who also have intellectual disability or severe regres-
sion. Previous attempts to define subtypes based on 
clinical evaluations were unreliable and inconsistent, 
he says, something that does families and patients no 
favors. And he points out that the sample of 17 partici-
pants with CDD is still relatively small. It is impossible 
to figure out the degree of heterogeneity that exists 
in CDD. “The reason we stay with the spectrum is 
because we haven’t found anything better.”
Dylan’s story continues
Dylan continued to lose speech skills. Two years ago, 
at 16, he was diagnosed with catatonia, a disorder 
characterized by stupor, mutism, loss of motor skills, 
and periods of hyperactivity that can be combative 
and destructive. Dylan has since started in a boarding 
school that specializes in autism and has experience 
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working with students who have catatonia. After 
over a year of working with him, they have found a 
communication system for him. Covell describes it 
as an “old-school” picture system—laminated icons. 
Many kids use iPads to communicate using pictures, 
but Dylan’s unpredictable behavior—he can become 
destructive when frustrated—makes that impractical. 
He can stay in the school until he is 21, and there is no 
clear answer for what will be best for him after that.
For Kim Covell, the most elusive mystery is 
the sense, shared by many people who have loved 
ones with CDD, that the old Dylan is still in there 
somewhere. He becomes verbal when he gets agitated, 
but he refers to people and events in his pre-CDD past—
teachers from preschool, classmates, things he did 
with his family. “There’s something—it’s there,” Covell 
says. “But it’s not.” /yale medicine



















Alexander Westphal and Abha 
Gupta led a research team that 
studied childhood disintegra-
tive disorder. Their findings on 
the disorder, they say, should 
push a rethinking of the defini-
tion of autism.
Melanoma is often fatal in humans, particularly when 
it metastasizes, spreading from the skin to other tis-
sues. Yet Lipizzaner stallions, the famed Viennese show 
horses, frequently develop skin cancer with no ill effects, 
in large part because the cancer tends not to spread 
in these horses. Since hearing about the melanoma-
resistant horses, Günter P. Wagner, Ph.D., an Austrian 
native himself, has been trying to understand why. The 
answer, he found, relates to the evolution of mamma-
lian pregnancy.
In many mammals, including humans, says Wagner, 
the fetus, via its sac-like placenta, invades the wall of 
the uterus, or implants, in much the same way that 
cancer metastasizes and invades new tissues. The 
hoofed mammals in which skin cancer does not metas-
tasize—including horses, cows, and pigs—are also 
those species in which the fetus does not implant, and 
Wagner believes that this is no coincidence. 
“If we investigate in cows or horses or pigs or 
whatever and see how they keep out invasive cell 
types—either the trophoblast, the placenta, or cancer 
cells—we may learn how to treat or contain or make 
less aggressive cancers in humans,” Wagner says.
Wagner, the Alison Richard Professor of Ecology 
and Evolutionary Biology, with a secondary appoint-
ment in the Department of Obstetrics, Gynecology and 
Reproductive Sciences, established his lab at Yale in 
1991 in the biology department at 165 Prospect Street. 
When West Campus opened 10 years ago, Wagner was 
the first investigator to move his lab to the new enclave, 
which promised myriad interdisciplinary opportuni-
ties. As a member of West Campus’ Systems Biology 
Institute and the new Cancer Systems Biology @Yale 
program, which bring together researchers from 
different disciplines to work on common problems, 
Wagner draws on the diverse expertise of his collabo-
rators as he explores the pregnancy-cancer link.
Other researchers had proposed that throughout 
the evolution of pregnancy, the aggressiveness of the 
fetus from a given species, like the strength of a bull-
dozer, determined the extent to which it invaded the 
uterus. Humans, for example, have invasive pregnan-
cies: the fetus burrows into the lining of the uterine 
wall. Horses, cows, and pigs, on the other hand, have 
noninvasive pregnancies: the fetus contacts the uter-
ine wall but does not burrow through it. Cow, pig, and 
horse fetuses, therefore, should be less aggressive than 
human ones. Wagner, however, says that the fetuses of 
hoofed mammals do not invade the uterine wall “not 
because the fetus became less aggressive; it’s because 
the mother found a way of keeping [the fetus] out.” It’s 
less the force of the invading fetus and more that of the 
uterus opposing the invasion that determines how far 
the fetus gets.
In collaboration with Andre Levchenko, Ph.D., 
director of the Systems Biology Institute and the John 
C. Malone Professor of Biomedical Engineering, the 
Wagner and Levchenko labs demonstrated how the 
uterine lining, the endometrium, fights the invading 
fetus. To simulate fetal invasion, the researchers set up 
placental cells to move along tiny grooves fabricated in 
the Levchenko lab as they pass through endometrial 
cells. Following the so-called nanogrooves, each one 
about 400 nanometers wide—about one-hundredth 
the width of a human hair—the cells move in a straight 
line, and researchers can easily measure their invasive 
progress. “That’s the basis for us being able to measure 
different rates of invasion that are going on,” Wagner 
explains. The result? Human placental cells travel far-
ther through human endometrial cells than they do 
by ashley p. taylor | vshivkova image
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through bovine endometrial cells—cow cells are resist-
ing the invasion.
The skin cells of pigs, cows, and horses, Wagner 
hypothesized, resisted melanoma metastasis in the 
same way that their wombs resisted fetal invasion. But 
what defenses could the skin and the uterus share? 
Both the endometrium and the skin contain cells called 
fibroblasts, and throughout the evolution of mammals, 
Wagner found, the fibroblasts in these two locations 
evolved together, such that as the uterus began to resist 
fetal implantation, so the skin began to resist mela-
noma metastasis. Nanogroove experiments supported 
the hypothesis: skin fibroblasts from cows resist mela-
noma invasion better than those from humans. 
In experiments with bovine melanoma cells, Wagner 
collaborates with another West Campus researcher, 
Sidi Chen, Ph.D., assistant professor of genetics in the 
Integrated Science and Technology Center. Cow mela-
noma cells are hard to come by, so “we have to make 
them ourselves,” Wagner says. Chen uses gene editing 
techniques to rewrite the genetic code of cow melano-
cytes and make them cancerous. “Our goal is to grow 
healthy melanocytes in the lab, and then we ask Chen 
to make them into tumor cells so that we can study cow 
melanoma cells,” Wagner says. 
To see whether human skin fibroblasts could be 
coaxed to resist invading melanoma, Wagner, in 
collaboration with the Levchenko lab, is modify-
ing human skin fibroblasts to make them more like 
fibroblasts from cows. So far, modified human cells 
are better able to resist melanoma invasion than their 
unmodified counterparts. “This is still preliminary, 
but promising,” says Wagner. /yale medicine
Ashley P. Taylor is a writer based in Brooklyn, N.Y.
Fibroblasts appear in both the 
skin and the womb. They may 
hold clues as to why horses, 
cows, and pigs resist melanoma.
Exome sequencing allows scientists  
and clinicians to zero in on the  
mutations responsible for a disparate 
array of ailments.
by bruce fellman | maya szatai illustration
About eight years ago, a doctor in Turkey examined a 
5-month-old boy for “failure to thrive and dehydra-
tion.” Paradoxically, his diapers were wet, so the medi-
cal team was inclined to suspect Bartter syndrome, a 
congenital kidney defect which is manageable if caught 
early. But the standard treatments weren’t working. 
Baffled, the doctors sent the infant’s blood sample to 
Yale for a sophisticated analysis then under develop-
ment called exome sequencing.
While the Human Genome Project and related 
work had looked at the entire genetic code and gen-
erated an unruly amount of data, exome sequencing 
detailed only the region of the genome—about 1 per-
cent—that codes for proteins. The technique was pio-
neered by School of Medicine researchers Shrikant M. 
Mane, Ph.D., director of the Yale Center for Genome 
Analysis (YCGA), and Richard P. Lifton, M.D., Ph.D., 
former chair of genetics who’s now president of 
Rockefeller University, and their colleagues. Exome 
sequencing, says Mane, “gives you just about every-
thing you need for diagnostic purposes, and quickly 
we knew this wasn’t a kidney problem. The doctors 
had been barking up the wrong tree.”
Exome sequencing revealed a mutation in gene 
SLC26A3, which leads to a condition called congeni-
tal chloride diarrhea. While the condition can’t be 
altered, prompt salt replacement therapy helped bring 
the baby back from the brink. “This was the first use 
of the exome sequencing technique as a diagnostic 
tool,” says Mane, who delights in explaining that his 
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Putting the precise in precision medicine
uncle in India underwent whole-exome analysis—and 
when Mane was trying to figure out the source of his 
own recent mysterious malaise, he also undertook 
the sequencing equivalent of a selfie. “Now, the whole 
world is using it.”
Since a seminal paper on this case appeared in 
2009 in the Proceedings of the National Academy 
of Sciences, Mane and his colleagues have employed 
exome sequencing to zero in on the exact muta-
tions responsible for a disparate array of ailments 
from severe brain malformations to unusual kinds of 
melanomas. The technique is rapidly becoming a key 
component in the toolkit that health care workers 
and researchers are using to achieve a long-standing 
dream: precision medicine.
In a presentation last February to the Connecticut 
Commission on Economic Competitiveness and 
the state legislature’s Commerce Committee, Dean 
Robert J. Alpern, M.D., Ensign Professor of Medicine, 
explained that precision medicine uses “a patient’s 
genomic information, environment, and lifestyle to 
assess a person’s risks for disease and to develop more 
effective and targeted treatment plans and therapies.” 
Doctors will be able to probe a patient’s DNA to deter-
mine in advance what will and won’t help an indi-
vidual, rather than the general population. “Ideally, 
we’ll also be able to develop an alternative therapy that 
worked for the non-responders,” says Alpern. “This 
is true precision medicine, and while today it has had 
some applications, for many conditions it remains a 
dream. But it is a dream that will soon be realized.”
Perhaps paradoxically, becoming more precise has 
required School of Medicine researchers and physicians 
alike to adopt an ever broader, more interdisciplinary 
approach to their work. Not only are investigators in 
the basic medical sciences, from pathologists and cell 
biologists to immunologists, collaborating with an 
array of front-line clinicians, but they’re also sharing 
an array of new tools and working closely with inves-
tigators throughout the entire university, from physi-
cists and chemists to mathematicians and computer 
scientists, to lay the groundwork for the move to a new 
kind of medicine.
One way this is being achieved is through the YCGA, 
a joint endeavor among the university, the School of 
Medicine, and Yale New Haven Hospital. Established in 
2009, the YCGA opened its new headquarters on West 
Campus in May and is using the highest of high-tech 
genome sequencers and computers to investigate the 
genetics of rare inherited diseases, uncover mutations 
that can help doctors diagnose ailments, and—this is 
the ultimate hope—discover individualized ways to 
deal with often baffling, even intractable, situations.
A multimillion-dollar array of state-of-the-art 
machinery and analysis equipment has been critical 
in bringing costs within reason. Mane noted that the 
Human Genome Project, the federal effort to sequence 
the complete genetic code, took some 10 years and 
$3 billion to complete; it was wrapped up in 2003. Yale 
geneticist Jonathan M. Rothberg, Ph.D. ’91, FW ’93, 
invented high-throughput sequencers that reduced the 
time considerably and lowered the cost of sequencing a 
human genome to about $1 million—subsequent tech-
nologies have dropped this expense to a few days of 
analysis time and a “mere” $1,000. Sequence only the 
exome, says Mane, and the work could be done in close 
to real time for approximately $275—about the cost of a 
routine office visit. “That’s why this revolution is start-
ing to take place,” says Mane. “Sequencing has become 
so cheap that we’re poised to take a quantum leap in 
our ability to use it routinely.”
There are, however, roadblocks—some technical or 
institutional, others structural or philosophical—that 
will have to be addressed. Among them is the chal-
lenge of locating a mutational needle in the genetic 
haystack. “It has become relatively easy to sequence 
a genome, but it’s still very hard to determine the 
genetic cause of a disease,” says Mane. Part of the rea-
son for the difficulty comes from the fundamental but 
surprising insight provided by the Human Genome 
Project: we simply don’t have that many genes. 
“We used to believe that it was one gene, one pro-
tein, so if there were 100,000 proteins, there had to be 
100,000 genes,” Mane says. “But we now know that we 
have only about a quarter of that number. In fact, we 
have fewer genes than a rice plant.”
The smaller number, however, makes life harder, 
not easier, for researchers, since those 20,000 genes are 
expert multitaskers, which makes identifying all their 
responsibilities especially challenging. Uncovering 
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which mutation leads to what ailment requires 
sequencing numerous individuals and keeping the 
YCGA’s pair of NovaSeq 6000s and related machinery 
working overtime. Building such genetic profiles and 
sorting the good from the bad also requires the analy-
sis of an almost unfathomable amount of data and the 
development of new techniques to mine and protect 
them. That is the mandate of a newly formed entity 
called the Yale Center for Biomedical Data Science.
Center co-director Mark B. Gerstein, Ph.D., the 
Albert L. Williams Professor of Biomedical Informatics, 
explains that succeeding with what researchers term 
“Big Data” requires “real thought about standards, the 
uniform collection of data, the distribution of samples, 
and the presentation and packaging of results.” After 
three years of planning, Gerstein and co-director 
Hongyu Zhao, Ph.D., a geneticist and the Ira V. Hiscock 
Professor of Biostatistics, have assembled a kind of 
central clearinghouse for research and development of 
these issues, particularly cloud computing and privacy, 
as well as for education and bridge-building collabora-
tion on university, national, and international levels. 
“Our mission is really about connecting and coordinat-
ing the people and resources already here, and becom-
ing a way to recruit the scientists we want to attract 
in the future for the Big Data initiatives we want to 
participate in,” says Gerstein. “We expect the center to 
have a very broad impact.”
Tamar S. Gendler, Ph.D., dean of Yale’s Faculty of 
Arts and Sciences, the Vincent J. Scully Professor of 
Philosophy, and professor of psychology and cogni-
tive sciences, concurs. At the university, she explains, 
data science encompasses three interlocking circles 
that range from the most abstract—pure mathemat-
ics—to the most applied, the clinical. “What’s exciting 
is the often unexpected ways that the math informs 
the physics, which informs the chemistry and the 
biology and the clinical work,” says Gendler, point-
ing to the work of Ronald R. Coifman, Ph.D., the 
Phillips Professor of Mathematics. His fundamen-
tal insights enabled precise information organiza-
tion methods, which, due to a collaboration with 
Frederick J. Sigworth, Ph.D. ’79, professor of cellular 
and molecular physiology, of biomedical engineering, 
and of molecular biophysics and biochemistry, led to 
remarkable enhancements in the images produced by 
the cryo-electron microscope. Those images can reveal 
the basic structure of molecules that may be important 
in understanding diseases and developing targeted 
therapies. “This device allows atomic structures to be 
determined from a smaller number of molecules—a 
millionfold smaller—compared to the more traditional 
method of X-ray crystallography. And the ability to 
obtain atomic structures with cryo-EM happened 
quickly—about five years from the initial theoretical 
math to an actual insertion into a scientific tool,” 
says Gendler. 
Steven H. Kleinstein, Ph.D., associate professor 
of pathology, is using the cutting-edge sequencing 
tools to better understand how the immune sys-
tem responds to pathogenic challenge, as well as 
to uncover the roots of autoimmune disorders like 
myasthenia gravis. Kleinstein targets the body’s 
100 billion B cells, a key component of the immune 
system, to discover the characteristics that enable 
each cell’s antibody receptors to recognize and fight 
off pathogens. “This is a powerful technique that lets 
us understand the dynamics of the process,” says 
Kleinstein. “We can use these data to reconstruct a 
person’s unique immunological history. This helps 
us understand the processes that led to a disease, or 
may eventually help us design better vaccines that 
can leverage an individual’s current immune state to 
get the exact response we want. Receptor sequencing 
is already being used as a personalized biomarker for 
certain kinds of tumors and can detect, with much 
greater sensitivity than established methods like flow 
cytometry, if the disease is coming back.  This kind of 
precision medicine is no longer a pie-in-the-sky idea. 
We’re going to get there.” /yale medicine
Bruce Fellman is a writer in North Stonington, Conn.
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When two experts in their fields get together and com-
bine their labs, incredible things happen. W. Mark 
Saltzman, Ph.D., the Goizueta Foundation Professor of 
Biomedical and Chemical Engineering, and his team 
designed “sticky particles”: nanoparticles that were bio-
adhesive and stuck to the surface of the skin. Combining 
this discovery with the expertise of Michael Girardi, 
M.D. ’92, HS ’97, FW ’97, professor of dermatology, the 
two used those sticky properties to create a sunscreen 
that blocks any toxins in the sunscreen from soaking 
through the skin and entering the bloodstream. 
Then they realized that they could take the technol-
ogy further. “We discovered that this adhesive property 
that adheres the nanoparticles to the skin also makes 
them attractive to tumor cells,” says Saltzman. Based 
on Saltzman’s previous success with a similar method 
to treat models of ovarian and other types of cancer, 
the team created a system that could adhere chemo-
therapeutic agents to tumors to treat skin cancer. While 
the team is still figuring out why these particles are 
attracted to tumor cells, the potential is obvious. 
As the collaboration continues, so do the discover-
ies: “We can keep expanding the technology in the lab,” 
says Girardi, “and see what else it can be used for.” But 
there are limits to what even super labs like Saltzman’s 
and Girardi’s can do. “You can’t, in a Yale lab, start 
developing a product,” Girardi notes.
Now, a new grant is poised to do just that and help 
them take their double discovery from the lab into the 
marketplace. With funding from the Blavatnik Family 
Foundation, Girardi and Saltzman seek to close the gap 
between the technology they have developed in the 
lab and the commercial world, where sunscreen can 
be sold to consumers and treatment can reach cancer 
patients via prescription. 
The purpose of the grant, which is in the range of 
$100,000 to $300,000, is to give Girardi and Saltzman the 
resources to bring their technology to the manufacturing 
stage, a critical step in getting it ultimately to consumers 
and patients. The demonstration of manufacturing at a 
larger scale will open the door to licensing the technol-
ogy or to beginning a start-up for advancing both appli-
cations of the technology to market. 
While Girardi and Saltzman can develop these 
products in the lab at a small scale, “there are ques-
tions surrounding how to make this cost-effective, 
and do it at a large scale, so that’s a very important 
step to bring this technology to the real world,” says 
Girardi. Through the grant, they will engage a con-
tract research organization to help them prepare to 
scale up the technology and perform preclinical test-
ing to answer such crucial questions for potential 
investors as quantifiable efficacy and levels of toxicity. 
There is a great deal of overlap, Girardi says, between 
how the sunscreen and skin cancer treatment would 
be developed, scaled up, and manufactured, but there 
are some fundamental differences. “There are differ-
ent levels of tolerable toxicity and sterility in prepa-
ration in each of those, not to mention the active 
ingredients are different,” Girardi says.
“It is difficult to translate research work into a com-
mercial venture,” says Saltzman. “Venture capitalists 
or commercial partners want to see certain kinds of 
development results that are difficult for academic 
labs to accomplish. … The goal of the Blavatnik Family 
Foundation is to provide dollars that are explicitly for 
this purpose.” 
As they prepare to engage with industry, Girardi 
and Saltzman continue to hone the technology they 
have developed. The sunscreen was first developed 
by jeanna canapari | maya szatai illustration
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with the agent padimate O, which blocks only the 
sun’s UVB rays. The new version now uses a combina-
tion of agents to achieve broad-spectrum coverage, to 
block not only UVB rays, but harmful UVA rays as well. 
The team is working on even further uses for the plat-
form. “One of the most exciting aspects of a platform 
technology is the capacity to expand it in other direc-
tions,” Girardi says. 
Both researchers say the disparate nature of their 
backgrounds makes such a breakthrough possible. “One 
of the things that makes it impactful is that our areas 
of expertise are so different, but we communicate well 
together,” says Saltzman, “so we can do things that nei-
ther of us could easily do alone.” /yale medicine
Jeanna Canapari is a writer in Guilford, Conn.
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Four years ago, when 
Maya Lodish, M.D. ’03, 
and her young daughter 
visited the Cushing Center 
for a scavenger hunt at 
Lodish’s class reunion, 
both were struck by the 
unfamiliar, even eerie set-
ting—and its contents. Soft 
warm lighting illuminated 
hundreds of jars contain-
ing brains and tumors 
excised in the last century 
by Harvey Cushing, M.D.
Known as America’s 
father of successful 
neurosurgery, Cushing 
tissues—and whether it 
might reveal genetic links 
connecting Cushing’s 
patients with contempo-
rary pituitary diseases. 
“I can’t express enough 
how important genet-
ics is,” Lodish said. “It 
goes hand in hand with 
the care of the patient.” 
Investigating the genes 
of long-deceased patients 
is “contributing to under-
standing the genetics of 
disease,” Spencer said. He 
and Lodish sought out a 
medical student to take 
introduced practices a 
century ago that reduced 
an 80 percent mortality 
rate to 8 percent, accord-
ing to Dennis D. Spencer, 
M.D., the Harvey and 
Kate Cushing Professor of 
Neurosurgery and former 
chair of the Department 
of Neurosurgery. Cushing 
also procured many, many 
brains for future research. 
Today, those brains, 
which once gathered dust 
in a basement storeroom at 
the medical school, have 
received fresh formalin—
and offer a renewed avenue 
for research. On seeing the 
specimens, Lodish won-
dered whether any DNA 
survived in the preserved 
up the investigation as a 
thesis topic. The under-
taking was a natural fit for 
Cynthia Tsay, who studied 
the history of medicine 
during her undergraduate 
years at Yale. 
“It was her dream-
come-true project,” 
Lodish said. In the early 
stages of the project, Tsay 
and Lodish were flip-
ping through Cushing’s 
clinical notes when 
they came across an 
intriguing patient. Today 
known simply as G.B.S., 
his photograph from 
Cushing’s autopsy report 
looked familiar to Lodish, 
one of the few people who 
regularly sees patients 
  A reunion visit leads to a search  
 for genetic clues to a brain disorder
 By Natasha Strydhorst
  Old specimens yield 
new clues to disease
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capsule
with the smattering of 
freckle-like pigmentation 
that could indicate a rare 
disorder called Carney 
complex. Symptoms  
vary, but G.B.S. was  
a patient with a pituitary 
tumor secreting excess 
growth hormone, re- 
sulting in a condition 
called acromegaly.
 “It was a fortuitous 
discovery,” Tsay said, 
“because all the pieces 
lined up.” The patient’s 
photograph and records 
from a century ago could 
between environmental 
factors and disease. 
“Cushing would find 
out where you came from, 
what your work was, 
what your background 
was,” said Terry Dagradi, 
the Cushing Center 
coordinator who orches-
trated the cataloging of 
Cushing’s images and 
records for the project. 
“You had to just get to the 
details of people’s lives 
and see if there was a hint 
of something that you 
could put together.” 
OPPOSITE Neurosurgeon 
Dennis Spencer examines a 
specimen from the Cushing 
Tumor Registry selected by 
Maya Lodish and Cynthia 
Tsay for their study.  Al-
though this patient sample 
did not appear in the final 
paper, it was identified  
as coming from a patient  
of interest.  
FAR LEFT A brain specimen 
and clinical notes from a pa-
tient known as G.B.S., in left 
in photo, yielded clues to 
the disorder called Carney  
complex. The disorder was 
traced to the patient’s 
genetic code. The larger 
skeleton was from another 
patient and used for com-
parison in the study.
LEFT The patient known 
as G.B.S. suffered from 
acromegaly, the result of a 
pituitary tumor secreting 
excess growth hormone. 
be matched to his brain 
specimen preserved in the 
Cushing Center. It fell to 




lessly in the lab,” Lodish 
said, “trying to isolate 
DNA from these samples.” 
The effort paid off in a 
posthumous diagnosis for 
G.B.S.: Carney complex 
was indeed written in 
his genetic code. Could 
she go back in time, Tsay 
would have a great deal 
to tell Cushing about 
his former patient. But 
Cushing would also have 
a great deal to tell current 
doctors about the link 
An inherent fascination  
with brains in jars enthrall-
ed Cushing in the 1900s, 
Lodish and her daughter 
in 2013, and continues to 
fascinate today’s visitors 
to the Cushing Center. “It 
does really spark the inter-
est of younger people,” 
Lodish said.
Dagradi recalls an 
architect’s young daughter 
visiting the center, peer-
ing up at the specimens, 
and wondering out loud 
whether they were still 
thinking. “It was this  
very sweet little moment,” 
she said. “And you think, 
‘Oh—they’re not thinking, 





















 M.D./Ph.D. student  
wins Soros Fellowship
»
since he arrived in new york city in 2006 as a 
16-year-old immigrant from Suriname, Lorenzo R. 
Sewanan has packed in what looks like a lifetime of 
experiences. Sewanan, who is in his sixth year of the 
M.D.–Ph.D. Program, worked on a team that has designed 
prize-winning firefighting robots. He’s volunteered 
with Curtin Volunteers, a student-led service group, in 
indigenous communities in Western Australia, where he 
worked on educational initiatives and community ser-
vice in mining towns. He’s won an international poetry 
prize and been interviewed by The New Yorker. And 
this engineer-poet-physician-in-training can fix a mean 
batch of yuca (cassava) fries. 
This year, Sewanan won a Paul & 
Daisy Soros Fellowship for New 
Americans, a two-year $90,000 
educational grant. He was one of 
just 30 immigrants nationwide 
to receive an award that drew 
1,775 applications. 
“I feel lucky,” Sewanan said. 
“I really appreciate getting to 
stand as a placeholder for all the 
great work that immigrants of 
all kinds are doing, trying to 
give back to American society.”
Sewanan was born to 
Guyanese parents in Suriname, 
a former Dutch colony in South 
America; the family’s ancestors 
were among a 20th-century dias-
pora that left India for what was 
then known as British Guyana to 
become indentured laborers. He 
and his younger sister Amanda 
grew up in Paramaribo speaking 
English and Dutch; their parents 
sold clothes, jewelry, and cosmet-
ics in a small shop. After Lorenzo 
finished the 11th grade, the family 
immigrated to the United States. 
He completed high school at a 
public school in Jamaica, Queens. 
That may sound like a painful 
transition, but it wasn’t bad. In 
Suriname, Sewanan explained, 
people from neighboring Guyana 
were subject to discrimination 
after fleeing political turmoil in 
the 70s and 80s.
“You get made fun of a lot for 
speaking Dutch with a Guyanese 
accent, or for speaking English, 
for instance,” he said. “When I 
moved to the States, I felt more 
at home. … Everyone was an 
immigrant from somewhere in 




writes poetry, has built 
robots, and has been in-
terviewed by The New 
Yorker. Now he’s in his 
sixth year of the M.D.–
Ph.D. Program, studying 
the human heart.
launched his interest in the 
medical humanities. Once he 
read physician-author Abraham 
Verghese’s memoir My Own 
Country—“an incredible jour-
ney”—he knew he wanted to 
explore medicine.
Drawn to Yale in part because 
of its robust medical humanities 
program, Sewanan kept writing. 
The next stop was harder for 
an immigrant from Suriname: 
affluent, mostly white Trinity 
College in Connecticut. “Fitting 
in was tough,” he recalls. He 
majored in physics and engi-
neering (hence the robots), with 
a minor in writing and rhetoric. 
Sewanan also worked as an EMT, 
mentored students in a “Physics 
in Science Fiction” class, and 
studied abroad in Perth.
When he was a sophomore, 
a workshop on reflective writ-
ing and literature in medicine 
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  “The heart is one of the most mechanical  
 organs—it’s so beautiful, and the purest version  















He co-founded a health profes-
sions literary journal, Murmurs. 
In 2013, he won the Marguerite 
Rush Lerner Award for poetry, as 
well as the Yale UCL Collaborative 
Poetry Competition. The latter 
award landed him in The New 
Yorker, where he appeared in a 
“Talk of the Town” story called  
“Poet, M.D.” 
When Sewanan isn’t writ-
ing poetry, he’s righting 
wrongs. In 2013, Sewanan co-
founded Students for a Better 
Healthcare System, in which 
medical students held teach-
ins in New Haven about health 
care access after the passage of 
the Affordable Care Act (ACA). 
For their efforts, the students 
received a 2015 Yale University 
Seton Elm-Ivy Award. 
For Sewanan, such activism 
is partly personal: prior to the 
ACA’s 2010 passage, he had fam-
ily and friends who struggled 
with spending caps, restrictions 
for preexisting conditions, and 
losing health insurance. “It was 
very obvious that this was stuff 
we should try to help people 
with,” he said. 
In 2015, Sewanan joined 
the Integrative Cardiac 
Biomechanics Lab of biomedi-
cal engineering professor Stuart 
Campbell, Ph.D. They’re work-
ing to grow new tissues made 
with stem cells from patients 
with cardiomyopathy. These tis-
sues can increase understanding 
of the disease and possibly lead 
to new therapies. 
 “The heart is one of the 
most mechanical organs—it’s so 
beautiful, and the purest version 
of biomechanics that we can get,” 
he said. “I also just love the idea of 
cardiology from a poetic sense as 
well. It’s very poetic to fix people’s 
hearts. … not to be too corny.”
In his spare time, Sewanan 
enjoys reading, writing, explor-
ing the outdoors, and tasting 
craft beers. And he likes to cook.
“I’m known for my yuca fries,” 
he said. “I love making stuff that 
reminds me of home.”
—Jenny Blair, M.D. ’04
»
A diagnosis of the 
health care system 
Robert M. “Robbie” Pearl, M.D. ’72, 
recalls the days nearly 15 years ago 
that changed his life—and ended 
his father’s. A series of medical 
miscommunications resulted in 
a medical error that a few years 
later in 2003 would lead to the 
premature death of his father, Jack. 
Myriad specialists tended to his 
father during this last hospital stay, 
each recommending a different 
operation. Once the family con-
cluded that no additional treat-
ment would lead to the quality of 
life his father would want, Pearl 
said, they declined further aggres-
sive procedures and the physicians 
stopped coming.
“There’s no CPT code for com-
passion,” Pearl said.
Now Pearl is on a mission 
to return compassion, expand 
prevention, and reduce medi-
cal errors in American medical 
practice. Pearl, who for 18 years 
was CEO of Permanente Medical 
Group and is now chair of the 
Council of Accountable Physician 
Practices, recently published his 
first book, Mistreated: Why  
We Think We’re Getting Good 
Health Care—and Why We’re 
Usually Wrong.
“I’ve heard fiction writers talk 
about the characters coming 
alive, but I think it’s just as true 
for nonfiction,” Pearl said. Not 
just characters, but memories, 
experiences, and convictions 
demand to be narrated—and the 
reasons for writing “start bub-
bling over.” His father’s death 
and his observations as a physi-
cian and CEO of Permanente 
solidified his conviction: there’s 
something rotten in the system 
of health care in this country.
After training at Stanford, 
Pearl began his career as a plas-
tic and reconstructive surgeon, 
enthralled with the specialty’s 
capacity to redirect the trajec-
tory of patients’ lives. “Plastic 
surgery is the rebuilding of life, 
not just the correction of dis-
ease,” Pearl said. 
Health, he believes, needs to 
be the focus of modern medi-
cal care. In contrast, medical 
practice in America was fixated 
primarily on correcting dis-
ease rather than preventing it 
in the first place. “I think that 
in many ways I’ve spent my 
entire career wanting to change 
American medicine, and this 
book has opened a new chapter,” 
Pearl said.
He describes medicine as 
an industry operating two 
centuries in the past. The 
When Esther Choo, 
M.D. ’01, tweeted about 
her emergency room 
encounters with white 
nationalists, she never 
expected her story to 
go viral. In the wake of 
the incidents in Char-
lottesville, her thread 
led to a live interview 
on CNN and an article 
in the Washington Post.
For more on Esther  





plastic surgery residency direc-
tor, training future physicians. 
“What I tell all of them about 
their future is that it’s going to 
be multiple careers,” Pearl said. 
The route to better health care, 
Pearl said, begins with acknowl-
edging medicine’s shortcomings—
and addressing them through a 
model of integrated, preventive, 
and compassionate care. This 
vision echoes the philosophy of 
Sidney R. Garfield, M.D., who 
co-founded Kaiser Permanente in 
1945: “We need a health care sys-
tem—not a disease system.”
—Natasha Strydhorst
Events in his personal 
and professional  
life led Robert Pearl  
to write a book  
about what he be-
lieves is wrong  
with the American 
health care system.
fee-for-service structure of 
payment resembles that used 
among the scattered British 
population of the 19th century, 
and paper-and-pencil record 
keeping belongs in the 20th 
century, Pearl said. America’s 
health care system is “as des-
tined to fail as the economy 
of England was before the 
Industrial Revolution,” he said. 
“What we need is a new revolu-
tion—a revolution that’s going 
to change the structure, and 
change economics, and change 
the technology.” According to 
Pearl, the structure of American 
health care is not integrated, 
but fragmented along specialty 
lines, with poor communication 
and patients falling through the 
cracks. A legion of specialists 
treated his father, he recalled, 
each assuming his father had 
received an essential vaccine 
following his spleen removal, 
and none administering it. 
In Mistreated, Pearl uses 
neurophysiological research to 
show how context shifts percep-
tion and changes behavior.  
For example, physicians— 
particularly specialists—need to 
communicate with those in other 
disciplines, he said. “When care 
is integrated, you see everyone as 
being on the same team as you. 
As a result, you’re going to col-
laborate with them. You’re going 
to cooperate. You’re going to 
coordinate. You’re going to inter-
act,” he said. “And as patients, 
most people assume that it’s hap-
pening in the health care they 
receive, but often it’s not.”
Pearl points to his experi-
ence at the School of Medicine 
as a contrast to this structural 
weakness. “My classmates were 
not my competitors. They were 
my partners,” he said. “It was 
the best environment I could 
have been in to understand col-
legiality and the power that it 
can have.” That same atmo-
sphere is one that, as CEO, 
Pearl strove to incorporate into 
Permanente Medical Group. His 
integrative approach extends 
to his own combined pursuits 
of medicine, management, and 
writing. He authors a health 
care and business column on 
Forbes.com, and serves on the 
faculty of Stanford’s medical and 
business schools. He has also 
spent eight years as Stanford’s 
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Peter G. Schulam, M.D., Ph.D., 
chair and professor of urology, is 
the inaugural faculty director of 
the center. No stranger to col-
laboration, in 2014 Schulam co-
founded the Center for Biomedical 
Innovation and Technology (CBIT) 
with W. Mark Saltzman, Ph.D., 
the Goizueta Foundation Professor 
of Biomedical Engineering, pro-
fessor of cellular and molecular 
physiology, and of chemical engi-
neering, to encourage physicians, 
engineering and medical students, 
and patients to invent devices for 
health care gaps. The success of 
CBIT led to an invitation to serve 
as faculty director of Tsai CITY. 
Schulam’s collaborative expe-
riences extend further back to 
his work as vice chair of urology 
at Ronald Reagan UCLA Medical 
Center. There he collaborated 
with architects and hospital 
administrators to design the hos-
pital’s second-floor surgical oper-
ating suites from the ground up. 
A native of New Haven, 
Schulam came to Yale in 2012 
to lead the newly formed 
Department of Urology at Yale 
New Haven Hospital. In the five 
years since, he has learned that 
persistence is the most powerful 
tool to bring projects to fruition. 
“Everyone has great ideas,” he 
said. “Very few people have the 
resilience to keep going despite 
unfavorable headwinds.”
  How Peter Schulam  
came to lead a center  
 for innovative thinking
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question and answer
A S S C I E NC E A N D R E S E A RC H MOV E away from a narrow 
focus within a field and toward efforts across disciplines, a gift 
from an alumnus of the Yale College Class of 1986 aims to spur 
such collaborations by establishing a home for innovation. In 
May, Joseph C. Tsai, J.D. ’90, co-founder and executive vice 
chair of Alibaba Group, the Chinese e-commerce company, 
made a donation through the Joe and Clara Tsai Foundation 
to support the construction and launch of the Tsai Center for 
Innovative Thinking at Yale (Tsai CITY). The 10,000-square-
foot building, which will be located on Prospect Street near the 
School of Engineering & Applied Science, is slated to open in 
2019, but the center’s basic operations are up and running. 
  How Peter Schulam  
came to lead a center  
 for innovative thinking





What will Tsai CITY do?  
This center will coalesce 
all innovative activi-
ties throughout the Yale 
campus, and we already 
have quite a few. We 
have a number of ongo-
ing innovative efforts 
including, to name a few, 
the Yale Entrepreneurial 
Institute, CBIT, the Office 
of Cooperative Research, 
the Center for Engineering 
Innovation & Design, the 
Center for Business and 
the Environment at Yale, 
the Social Innovation 
Lab at Dwight Hall, and 
InnovateHealth Yale. The 
idea is to support what 
others have done, and cre-
ate connectivity to build a 
network. Each organiza-
tion is like a single candle 
burning. If we bring all the 
candles together, then the 
lumen output will be much 
higher. It will be a place that 
gives students in all Yale 
schools a space to work on 
a new invention, a process 
improvement, or to increase 
the efficiency of technology 
that already exists. 
How are innovation and 
interdisciplinary work 
intertwined? I once 
read about a concept that 
encompasses what we 
are trying to do: “Look 
for similarity in dis-
similar things.” It’s really 
difficult to be innova-
tive when you are with 
individuals in your same 
field. You want to shake it 
up. You have to be taken 
outside of your element 
and kind of repositioned 
to see new opportunities. 
And you also have to be 
willing to be spun a little 
bit. That is not necessar-
ily comfortable, but the 
more we get our students 
to experience that, the 
more successful and 
uniquely educated they 
will be, and the greater 
the impact that students 
can have beyond Yale and 
New Haven.
What is a key ingredient 
for working well among 
disciplines? First, you 
have to be inclusive, not 
exclusive. Whoever wants 
to participate is welcome 
to get involved. A success 
metric for the center will 
not be the number of ven-
tures created, but rather 
the engagement of the 
community. For example, 
how many people from 
how many different 
schools and programs 
are involved? The second 
idea we will emphasize 
is that innovation isn’t 
about ownership. People 
want to say that an idea 
is theirs, but that creates 
a wall, and we need to 
think bigger.




involves failure. What 
advice do you have for 
students on this? This 
isn’t something you can 
give advice about. CITY 
will be a safe space for 
failure. It does not have 
a curricular component—
nothing is being recorded. 
The only thing that 
matters is the eventual 
success. No one needs 
to know that a project 
went through 55 failures 
or reiterations before 
becoming a success. We 
aim to create an environ-
ment that will allow stu-
dents and collaborators to 
experience that. There’s 
nothing I can really say 
to students—they have to 
experience the process for 
themselves. We want fail-
ure and success to be part 
of their education here so 
they can take that with 
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   Life on Ice: A History  
of New Uses for Cold Blood
    By Cathy Shufro
Many of us have donated 
tissue for research without 
knowing it, according to 
Joanna Radin, Ph.D., associ-
ate professor in the history 
of medicine. If we’ve had a 
blood test or biopsy, or given 
birth in a hospital, then 
frozen specimens from our 
bodies may live on in labora-
tory freezers—blood, biopsied 
tissue, a snippet of umbilical 
cord. As of 2015, there were 
an estimated 600 million 
frozen human tissue speci-
mens in the United States, 
accumulating at the rate of 
20 million per year. In a new 
scholarly history, Life on Ice: 
A History of New Uses for 
Cold Blood, Radin explores 
the terra incognita of the 
“invisible infrastructure” that 
preserves human tissue.
Many people have read 
about one such tissue sample, 
as recounted in the 2010 
bestseller The Immortal Life 
of Henrietta Lacks. Author 
Rebecca Skloot describes how 
in 1951, before the advent of 
informed consent, a biologist 
at Johns Hopkins Hospital 
used cells taken from Lacks 
to establish an important cell 
line for cancer research. But 
Lacks is not unusual in hav-
ing unwittingly donated her 
tissue to science. As Radin 
points out, “There are mil-
lions and millions of other 
samples, including maybe 
even your own.” 
She explores not only 
the practical challenges but 
also the spiritual and ethical 
quandaries that arise from 
preserving “latent life”: Is 
frozen tissue alive or dead? 
Does the donor retain a claim 
to that tissue? “These are the 
kinds of questions that start 
to emerge when we pry open 
the freezer door,” says Radin.
In a book rich with meta-
phor, Radin describes how 
the need for transfusions 
on World War II battlefields 
advanced cold storage. After 
the war, cattle breeders 
pushed forward cold technol-
ogy by using liquid nitrogen 
to refrigerate sperm used by 
itinerant inseminators. In 
light of the atomic bomb-
ing of Hiroshima, biologists, 
geneticists, and epidemiolo-
gists began to worry about 
the health effects of radiation 
and chemical pollution. They 
reasoned that blood col-
lected from remote places 
where “primitive” people 
lived, supposedly closer to 
nature, would serve as a 
baseline for knowledge about 
human health. These scientists 
“adopted the freezer as a time 
capsule that might prove use-
ful in ways they could not even 
predict,” says Radin. A writer 
for the popular Life magazine 
nonetheless did make a predic-
tion, speculating in 1952 that 
“spermatozoa from exceptional 
males could be saved to fertil-
ize females of the future.”
Stored blood has indeed 
provided new information. 
For instance, blood collected 
in eastern Africa proved the 
hypothesis that the sickle 
cell trait evolved in response 
to the environment, as pro-
tection against malaria. In 
1985, researchers from WHO 
found the first known trace 
of HIV-1 in human blood col-
lected in the Congo in 1959.
But some donors have 
come to view the removal of 
blood from their communi-
ties as “biocolonialism.” The 
Yanomami community in the 
Amazon region demanded that 
blood collected in the 1960s 
be returned, in part because 
the donors had no control over 
how their blood was used for 
research. “Science is not a 
god who knows what is best 
for everybody,” a spokesper-
son told the press. While the 
community celebrated the 
return of 2,693 blood samples 
in 2015, Radin writes that for 
scientists, relinquishing the 
blood “was experienced as a 
loss of part of the vital legacy 
of science.”
Writing her book, Radin 
says, “has made me think 
differently about the bounda-
ries between being alive and 
being dead.” When she goes 
to the Yale Health Center for 
a routine blood test, she says 
she thinks, “This material 
might outlive me. Does it 
become its own life form with 
its own lifespan?” And she 
recognizes that her blood has 
a different significance for her 
than it will if it goes into a 
laboratory freezer: “My con-
cern about being sick or well 
is contributing to someone 
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ON T H E F I R S T W E E K E N D I N AUGUS T, 30 incoming members of the Class of 2021 spent three days in 
the High Peaks Wilderness Area of the Adirondacks in New York as part of the annual Medical Outdoor 
Orientation Trip. In groups of six accompanied by two second-year team leaders, the students hiked 
along trails that ranged from easy—up to four miles a day—to more challenging routes of seven to 10 
miles. During the hike, they carried their own sleeping bags and pads, cooking gear, bear canisters, and 
food—tortillas, cous cous, and cheese. The excursion often becomes a bonding experience that leads 
to lasting friendships. “When you’re in the woods,” said second-year student Libby Fairless, one of the 
organizers, “you have to drop any pretense. You’re dirty, you stink, and you’re tired.”
At the trailhead, group leaders Lindsay Eysenbach (left) and Andrew White (right) and incom-
ing students Sangwon Yun, Alexandra Junn, Michael Shang, Kristin Yu, Osama Ahmed, and Prerak 
Juthani took a leap in the air before their hike.
—John Curtis
 Bonding through hiking
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end note
